TY 2012 Form 990

(A) Name and Title	(B) Average hours per week (list any hours for related organizations below dotted line)	(C) Position (do not check more than one box, unless person is both an officer and a director/trustee)	(E) Reportable compensation from related organizations (W- 2/1099-MISC)
(1) Michael J Fox........................................................................ Founder	2.0 .......................	X
(2) Robert W Shackleton........................................................................ Chairman	2.0 .......................	X	X
(3) George E Prescott........................................................................ VICE CHAIRMAN	2.0 .......................	X	X
(4) Fred G Weiss........................................................................ Treasurer	2.0 .......................	X	X
(5) Holly S Andersen MD........................................................................ Member	2.0 .......................	X
(6) Eva Andersson-Dubin MD........................................................................ Member	2.0 .......................	X
(7) Jon Brooks........................................................................ Member	2.0 .......................	X
(8) Mark Booth........................................................................ Member	2.0 .......................	X
(9) Barry J Cohen........................................................................ Member	2.0 .......................	X
(10) Donny Deutsch........................................................................ Member	2.0 .......................	X
(11) David Einhorn........................................................................ Member	2.0 .......................	X
(12) Karen Finerman........................................................................ Member	2.0 .......................	X
(13) Nelle Fortenberry........................................................................ Member	2.0 .......................	X
(14) Albert B Glickman........................................................................ Member	2.0 .......................	X
(15) David Golub........................................................................ Member	2.0 .......................	X
(16) Mark L Hart III........................................................................ Member	2.0 .......................	X
(17) Skip Irving........................................................................ Member	2.0 .......................	X

(A) Name and Title	(B) Average hours per week (list any hours for related organizations below dotted line)	(C) Position (do not check more than one box, unless person is both an officer and a director/trustee)	(E) Reportable compensation from related organizations (W- 2/1099-MISC)	(F) Estimated amount of other compensation from the organization and related organizations
(18) Edward Kalikow........................................................................ Member	2.0 .......................	X				0	0
(19) Katheen Kennedy........................................................................ Member	2.0 .......................	X				0	0
(20) Amar Kuchinad........................................................................ Member	2.0 .......................	X				0	0
(21) Edwin A Levy........................................................................ Member	2.0 .......................	X				0	0
(22) Marc S Lipschultz........................................................................ Member	2.0 .......................	X				0	0
(23) Douglas I Ostrover........................................................................ Member	2.0 .......................	X				0	0
(24) Tracy Pollan........................................................................ Member	2.0 .......................	X				0	0
(25) Ryan Reynolds........................................................................ Member	2.0 .......................	X				0	0
(26) Frederick E Rowe Jr........................................................................ Member	2.0 .......................	X				0	0
(27) Lily Safra........................................................................ Member	2.0 .......................	X				0	0
(28) Curtis Schenker........................................................................ Member	2.0 .......................	X				0	0
(29) George Whelen........................................................................ Member	2.0 .......................0.0	X				0	0
(30) Todd Sherer........................................................................ CEO	40.0 .......................		X			445,616	26,090
(31) Joanne Martz........................................................................ Chief Fin and Admin Officer	40.0 .......................		X			295,473	20,048
(32) Deborah W Brooks........................................................................ Co-Founder & Exec. Vice Chair	40.0 .......................			X		510,660	26,090
(33) Sohini Chowdhury........................................................................ Sr. VP, Research Partnerships	40.0 .......................			X		210,396	12,452
(34) Sheila Kelly........................................................................ VP, Development	40.0 .......................			X		184,863	11,685
(35) Holly Teichholtz........................................................................ VP, Marketing & Communications	40.0 .......................				X	145,286	16,907
(36) Brian K Fiske........................................................................ VP, Research Programs	40.0 .......................				X	186,700	17,935
(37) Mark A Frasier........................................................................ VP, Research Programs	40.0 .......................				X	177,852	5,335
(38) Alison Urkowitz........................................................................ VP, Research Operations	40.0 .......................				X	145,290	10,499
(39) Laxmi Wordham........................................................................ Chief Digital Officer	40.0 .......................				X	230,440	25,503

Do not include amounts reported on lines 6b, 7b, 8b, 9b, and 10b of Part VIII.	(A) Total expenses	(B) Program service expenses	(C) Management and general expenses	(D) Fundraising expenses
1	Grants and other assistance to governments and organizations in the United States. See Part IV, line 21	37,825,367	37,825,367
2	Grants and other assistance to individuals in the United States. See Part IV, line 22	0
3	Grants and other assistance to governments, organizations, and individuals outside the United States. See Part IV, lines 15 and 16	17,254,498	17,254,498
4	Benefits paid to or for members	0
5	Compensation of current officers, directors, trustees, and key employees ....	1,647,008	807,034	263,521	576,453
6	Compensation not included above, to disqualified persons (as defined under section 4958(f)(1)) and persons described in section 4958(c)(3)(B) ....	0
7	Other salaries and wages	5,525,647	2,709,020	863,425	1,953,202
8	Pension plan accruals and contributions (include section 401(k) and 403(b) employer contributions) ....	188,491	95,280	28,151	65,060
9	Other employee benefits .......	609,410	266,543	110,539	232,328
10	Payroll taxes ...........	488,022	242,038	72,573	173,411
11	Fees for services (non-employees):
a	Management ......	0
b	Legal .........	108,454	98,250	731	9,473
c	Accounting ...........	37,662		37,662
d	Lobbying ...........	0
e	Professional fundraising services. See Part IV, line 17	0
f	Investment management fees ......	0
g	Other (If line 11g amount exceeds 10% of line 25, column (A) amount, list line 11g expenses on Schedule O) ........	644,425	411,358	27,751	205,316
12	Advertising and promotion ....	155,901	68,519		87,382
13	Office expenses .......	809,810	362,312	48,725	398,773
14	Information technology ......	407,580	188,218	18,941	200,421
15	Royalties ..	0
16	Occupancy ...........	1,461,819	730,941	225,757	505,121
17	Travel ............	393,081	126,021	15,094	251,966
18	Payments of travel or entertainment expenses for any federal, state, or local public officials ......	0
19	Conferences, conventions, and meetings ....	1,059,786	1,059,786
20	Interest ...........	56,420		56,420
21	Payments to affiliates .......	0
22	Depreciation, depletion, and amortization .....	668,503	317,027	50,375	301,101
23	Insurance ..............	67,055	54,795	3,013	9,247
24	Other expenses. Itemize expenses not covered above (List miscellaneous expenses in line 24e. If line 24e amount exceeds 10% of line 25, column (A) amount, list line 24e expenses on Schedule O.)
a	CREDIT CARD & BROKERAGE FEES	310,526	326	15,603	294,597
b	OTHER SPECIAL EVENTS EXPENSE	209,094			209,094
c	DONATION PROCESSING	78,827			78,827
d	MARATHON RUNNER FEES	178,983			178,983
e	All other expenses	60,422	40,230	4,115	16,077
25	Total functional expenses. Add lines 1 through 24e	70,246,791	62,657,563	1,842,396	5,746,832
26	Joint costs. Complete this line only if the organization reported in column (B) joint costs from a combined educational campaign and fundraising solicitation. Check here if following SOP 98-2 (ASC 958-720).

Part X Balance Sheet Check if Schedule O contains a response to any question in this Part X ...............
	1	Cashnon-interest-bearing .............	104	1	326
2	Savings and temporary cash investments .........	80,371,171	2	85,393,127
3	Pledges and grants receivable, net ...........	12,027,926	3	15,199,335
4	Accounts receivable, net .............	0	4	0
5	Loans and other receivables from current and former officers, directors, trustees, key employees, and highest compensated employees. Complete Part II of Schedule L ..................
		0	5	0
6	Loans and other receivables from other disqualified persons (as defined under section 4958(f)(1)), persons described in section 4958(c)(3)(B), and contributing employers and sponsoring organizations of section 501(c)(9) voluntary employees' beneficiary organizations (see instructions) Complete Part II of Schedule L
		0	6	0
7	Notes and loans receivable, net .............	0	7	0
8	Inventories for sale or use ..............	17,847	8	19,190
9	Prepaid expenses and deferred charges ..........	303,256	9	312,174
10a	Land, buildings, and equipment: cost or other basis. Complete Part VI of Schedule D	10a	3,832,472
b	Less: accumulated depreciation .....	10b	1,688,083	653,423	10c	2,144,389
11	Investments—publicly traded securities ..........	1,339,815	11	1,478,589
12	Investments—other securities. See Part IV, line 11 .....	0	12	0
13	Investments—program-related. See Part IV, line 11 .....	0	13	0
14	Intangible assets ...............	0	14	0
15	Other assets. See Part IV, line 11 ...........	828,698	15	831,373
16	Total assets. Add lines 1 through 15 (must equal line 34)......	95,542,240	16	105,378,503
	17	Accounts payable and accrued expenses .........	1,590,225	17	2,186,550
18	Grants payable .................	56,245,521	18	62,405,623
19	Deferred revenue ................	14,898,701	19	0
20	Tax-exempt bond liabilities .............	0	20	0
21	Escrow or custodial account liability. Complete Part IV of Schedule D..	0	21	0
22	Loans and other payables to current and former officers, directors, trustees, key employees, highest compensated employees, and disqualified
	persons. Complete Part II of Schedule L..........	0	22	0
23	Secured mortgages and notes payable to unrelated third parties ..	0	23	0
24	Unsecured notes and loans payable to unrelated third parties ....	1,000,196	24	1,150,196
25	Other liabilities (including federal income tax, payables to related third parties, and other liabilities not included on lines 17-24). Complete Part X of Schedule D....................	685,752	25	1,218,595
26	Total liabilities. Add lines 17 through 25.........	74,420,395	26	66,960,964
		Organizations that follow SFAS 117 (ASC 958), check here and complete lines 27 through 29, and lines 33 and 34.
27	Unrestricted net assets ..............	5,774,290	27	18,533,026
28	Temporarily restricted net assets ...........	15,347,555	28	19,884,513
29	Permanently restricted net assets ...........	0	29	0
	Organizations that do not follow SFAS 117 (ASC 958), check here and complete lines 30 through 34.
30	Capital stock or trust principal, or current funds ........		30
31	Paid-in or capital surplus, or land, building or equipment fund .....		31
32	Retained earnings, endowment, accumulated income, or other funds		32
33	Total net assets or fund balances ...........	21,121,845	33	38,417,539
34	Total liabilities and net assets/fund balances ........	95,542,240	34	105,378,503

- TIN:

SCHEDULE A
(Form 990 or 990EZ)

Department of the Treasury
Internal Revenue Service

Public Charity Status and Public Support

Complete if the organization is a section 501(c)(3) organization or a section
4947(a)(1) nonexempt charitable trust.

Attach to Form 990 or Form 990-EZ. right arrow

See separate instructions.

OMB No. 1545-0047

2012

Open to Public
Inspection

Name of the organization

THE MICHAEL J FOX FOUNDATION
FOR PARKINSON'S RESEARCH

Employer identification number

13-4141945

Part I

Reason for Public Charity Status (All organizations must complete this part.) See instructions.

The organization is not a private foundation because it is: (For lines 1 through 11, check only one box.)

A church, convention of churches, or association of churches described in section 170(b)(1)(A)(i).

A school described in section 170(b)(1)(A)(ii). (Attach Schedule E.)

A hospital or a cooperative hospital service organization described in section 170(b)(1)(A)(iii).

A medical research organization operated in conjunction with a hospital described in section 170(b)(1)(A)(iii). Enter the hospital's name, city, and state:

An organization operated for the benefit of a college or university owned or operated by a governmental unit described in

section 170(b)(1)(A)(iv). (Complete Part II.)

A federal, state, or local government or governmental unit described in section 170(b)(1)(A)(v).

An organization that normally receives a substantial part of its support from a governmental unit or from the general public described in section 170(b)(1)(A)(vi). (Complete Part II.)

A community trust described in section 170(b)(1)(A)(vi). (Complete Part II.)

An organization that normally receives: (1) more than 331/3% of its support from contributions, membership fees, and gross

receipts from activities related to its exempt functions—subject to certain exceptions, and (2) no more than 331/3% of

its support from gross investment income and unrelated business taxable income (less section 511 tax) from businesses

acquired by the organization after June 30, 1975. See section 509(a)(2). (Complete Part III.)

An organization organized and operated exclusively to test for public safety. See section 509(a)(4).

An organization organized and operated exclusively for the benefit of, to perform the functions of, or to carry out the purposes of one or more publicly supported organizations described in section 509(a)(1) or section 509(a)(2). See section 509(a)(3). Check the box that describes the type of supporting organization and complete lines 11e through 11h.

Type I

Type II

Type III - Functionally integrated

Type III - Non-functionally integrated

By checking this box, I certify that the organization is not controlled directly or indirectly by one or more disqualified persons other than foundation managers and other than one or more publicly supported organizations described in section 509(a)(1) or section 509(a)(2).

If the organization received a written determination from the IRS that it is a Type I, Type II, or Type III supporting organization, check this box ..................................................

Since August 17, 2006, has the organization accepted any gift or contribution from any of the
following persons?

(i) A person who directly or indirectly controls, either alone or together with persons described in (ii)

Yes

and (iii) below, the governing body of the supported organization? ................

11g(i)

(ii) A family member of a person described in (i) above? ......................

11g(ii)

(iii) A 35% controlled entity of a person described in (i) or (ii) above? ................

11g(iii)

Provide the following information about the supported organization(s).

(i) Name of supported organization	(ii) EIN	(iv) Is the organization in col. (i) listed in your governing document?		(v) Did you notify the organization in col. (i) of your support?		(vi) Is the organization in col. (i) organized in the U.S.?		(vii) Amount of monetary support
(i) Name of supported organization	(ii) EIN	Yes	No	Yes	No	Yes	No	(vii) Amount of monetary support


Total

For Paperwork Reduction Act Notice, see the Instructions for Form 990 or 990EZ.

Cat. No. 11285F

Schedule A (Form 990 or 990-EZ) 2012

Page 2

Part II

Support Schedule for Organizations Described in Sections 170(b)(1)(A)(iv) and 170(b)(1)(A)(vi)
(Complete only if you checked the box on line 5, 7, or 8 of Part I or if the organization failed to qualify under Part III. If the organization fails to qualify under the tests listed below, please complete Part III.)

Section A. Public Support

Calendar year (or fiscal year beginning in)		(a) 2008	(b) 2009	(c) 2010	(d) 2011	(e) 2012	(f) Total
1	Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") ....	42,077,867	51,259,577	57,125,384	64,970,818	87,327,249	302,760,895
2	Tax revenues levied for the organization's benefit and either paid to or expended on its behalf.......						0
3	The value of services or facilities furnished by a governmental unit to the organization without charge..						0
4	Total. Add lines 1 through 3	42,077,867	51,259,577	57,125,384	64,970,818	87,327,249	302,760,895
5	The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f)..						140,078,581
6	Public support. Subtract line 5 from line 4.						162,682,314

Section B. Total Support

Calendar year (or fiscal year beginning in)		(a) 2008	(b) 2009	(c) 2010	(d) 2011	(e) 2012	(f) Total
7	Amounts from line 4..	42,077,867	51,259,577	57,125,384	64,970,818	87,327,249	302,760,895
8	Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources...	744,930	157,415	232,554	42,326	24,221	1,201,446
9	Net income from unrelated business activities, whether or not the business is regularly carried on..						0
10	Other income. Do not include gain or loss from the sale of capital assets (Explain in Part IV.)..	25,682	15,213	34,177	38,514	21,757	135,343
11	Total support (Add lines 7 through 10).						304,097,684

Gross receipts from related activities, etc. (see instructions) ..................

First five years. If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a 501(c)(3) organization, check this box and stop here........................................ right arrow

Section C. Computation of Public Support Percentage

Public support percentage for 2012 (line 6, column (f) divided by line 11, column (f)) .........

53.497 %

Public support percentage for 2011 Schedule A, Part II, line 14 ...............

59.094 %

16a

33 1/3% support test—2012. If the organization did not check the box on line 13, and line 14 is 33 1/3% or more, check this box
and stop here. The organization qualifies as a publicly supported organization ....................... right arrow

33 1/3% support test—2011. If the organization did not check a box on line 13 or 16a, and line 15 is 33 1/3% or more, check this
box and stop here. The organization qualifies as a publicly supported organization ..................... right arrow

17a

10%-facts-and-circumstances test—2012. If the organization did not check a box on line 13, 16a, or 16b, and line 14
is 10% or more, and if the organization meets the "facts-and-circumstances" test, check this box and stop here. Explain
in Part IV how the organization meets the "facts-and-circumstances" test. The organization qualifies as a publicly supported
organization ..................................................... right arrow

10%-facts-and-circumstances test—2011. If the organization did not check a box on line 13, 16a, 16b, or 17a, and line
15 is 10% or more, and if the organization meets the "facts-and-circumstances" test, check this box and stop here.
Explain in Part IV how the organization meets the "facts-and-circumstances" test. The organization qualifies as a publicly
supported organization ................................................ right arrow

Private foundation. If the organization did not check a box on line 13, 16a, 16b, 17a, or 17b, check this box and see
instructions ..................................................... right arrow

Schedule A (Form 990 or 990-EZ) 2012

Page 3

Part III

Support Schedule for Organizations Described in Section 509(a)(2)
(Complete only if you checked the box on line 9 of Part I or if the organization failed to qualify under Part II. If the organization fails to qualify under the tests listed below, please complete Part II.)

Section A. Public Support

Calendar year (or fiscal year beginning in)		(a) 2008	(b) 2009	(c) 2010	(d) 2011	(e) 2012	(f) Total
1	Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") .
2	Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose......
3	Gross receipts from activities that are not an unrelated trade or business under section 513..
4	Tax revenues levied for the organization's benefit and either paid to or expended on its behalf...
5	The value of services or facilities furnished by a governmental unit to the organization without charge..
6	Total. Add lines 1 through 5.
7a	Amounts included on lines 1, 2, and 3 received from disqualified persons...
b	Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year.
c	Add lines 7a and 7b..
8	Public support (Subtract line 7c from line 6.)

Section B. Total Support

Calendar year (or fiscal year beginning in)		(a) 2008	(b) 2009	(c) 2010	(d) 2011	(e) 2012	(f) Total
9	Amounts from line 6...
10a	Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources..
b	Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975.
c	Add lines 10a and 10b.
11	Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on.
12	Other income. Do not include gain or loss from the sale of capital assets (Explain in Part IV.) ..
13	Total support. (Add lines 9, 10c, 11, and 12.)..

First five years. If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a 501(c)(3) organization,
check this box and stop here............................................. right arrow

Section C. Computation of Public Support Percentage

Public support percentage for 2012 (line 8, column (f) divided by line 13, column (f)) .........

Public support percentage from 2011 Schedule A, Part III, line 15 ...............

Section D. Computation of Investment Income Percentage

Investment income percentage for 2012 (line 10c, column (f) divided by line 13, column (f)) ......

Investment income percentage from 2011 Schedule A, Part III, line 17 .............

19a

33 1/3% support tests—2012. If the organization did not check the box on line 14, and line 15 is more than 33 1/3%, and line 17 is not more than 33 1/3%, check this box and stop here. The organization qualifies as a publicly supported organization ........ right arrow

33 1/3% support tests—2011. If the organization did not check a box on line 14 or line 19a, and line 16 is more than 33 1/3% and line 18 is not more than 33 1/3%, check this box and stop here. The organization qualifies as a publicly supported organization ..... right arrow

Private foundation. If the organization did not check a box on line 14, 19a, or 19b, check this box and see instructions ..... right arrow

Schedule A (Form 990 or 990-EZ) 2012

Page 4

Part IV

Supplemental Information. Complete this part to provide the explanations required by Part II, line 10; Part II, line 17a or 17b; and Part III, line 12. Also complete this part for any additional information. (See instructions).

Facts And Circumstances Test

Explanation

Schedule A (Form 990 or 990-EZ) 2012

Additional Data

Software ID:
Software Version:

- TIN:

Schedule B
(Form 990, 990-EZ,
or 990-PF)

Department of the Treasury
Internal Revenue Service

Schedule of Contributors

Attach to Form 990, 990-EZ, or 990-PF.

OMB No. 1545-0047

2012

Name of the organization

THE MICHAEL J FOX FOUNDATION
FOR PARKINSON'S RESEARCH

Employer identification number

13-4141945

Organization type (check one):

Filers of:

Section:

Form 990 or 990-EZ

501(c)( ) (enter number) organization

4947(a)(1) nonexempt charitable trust not treated as a private foundation

527 political organization

Form 990-PF

501(c)(3) exempt private foundation

4947(a)(1) nonexempt charitable trust treated as a private foundation

501(c)(3) taxable private foundation

Check if your organization is covered by the General Rule or a Special Rule.
Note. Only a section 501(c)(7), (8), or (10) organization can check boxes for both the General Rule and a Special Rule. See instructions.

General Rule

For an organization filing Form 990, 990-EZ, or 990-PF that received, during the year, $5,000 or more (in money or
property) from any one contributor. Complete Parts I and II.

Special Rules

For a section 501(c)(3) organization filing Form 990 or 990-EZ that met the 33¹/3% support test of the regulations
under sections 509(a)(1) and 170(b)(1)(A)(vi) and received from any one contributor, during the year, a contribution of the
greater of (1) $5,000 or (2) 2% of the amount on (i) Form 990, Part VIII, line 1h, or (ii) Form 990-EZ, line 1. Complete Parts I and II.

For a section 501(c)(7), (8), or (10) organization filing Form 990 or 990-EZ that received from any one contributor,
during the year, total contributions of more than $1,000 for use exclusively for religious, charitable,
scientific, literary, or educational purposes, or the prevention of cruelty to children or animals. Complete Parts I, II, and
III.

For a section 501(c)(7), (8), or (10) organization filing Form 990 or 990-EZ that received from any one contributor,
during the year, contributions for use exclusively for religious, charitable, etc., purposes, but these contributions did
not total to more than $1,000. If this box is checked, enter here the total contributions that were received during
the year for an exclusively religious, charitable, etc., purpose. Do not complete any of the parts unless the General Rule
applies to this organization because it received nonexclusively religious, charitable, etc., contributions of $5,000 or more
during the year ......................... Arrow Bullet

Caution. An organization that is not covered by the General Rule and/or the Special Rules does not file Schedule B (Form 990,
990-EZ, or 990-PF), but it must answer “No” on Part IV, line 2 of its Form 990; or check the box on line H of its
Form 990-EZ or on Part I, line 2 of its Form 990-PF, to certify that it does not meet the filing requirements of Schedule B (Form 990,
990-EZ, or 990-PF).

For Paperwork Reduction Act Notice, see the Instructions
for Form 990, 990-EZ, or 990-PF.

Cat. No. 30613XSchedule B (Form 990, 990-EZ, or 990-PF) (2012)

Schedule B (Form 990, 990-EZ, or 990-PF) (2012)

Page 2

Name of organization THE MICHAEL J FOX FOUNDATION FOR PARKINSON'S RESEARCH

Part I	Contributors (see instructions). Use duplicate copies of Part I if additional space is needed.
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
RESTRICTED	RESTRICTED RESTRICTED RESTRICTED RESTRICTED, RESTRICTED RESTRICTED	$RESTRICTED	Person Payroll Noncash (Complete Part II if there is a noncash contribution.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II if there is a noncash contribution.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II if there is a noncash contribution.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II if there is a noncash contribution.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II if there is a noncash contribution.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II if there is a noncash contribution.)
Schedule B (Form 990, 990-EZ, or 990-PF) (2012)

Schedule B (Form 990, 990-EZ, or 990-PF) (2012)

Page 3

Name of organization THE MICHAEL J FOX FOUNDATION FOR PARKINSON'S RESEARCH

Part II	Noncash Property (see instructions). Use duplicate copies of Part II if additional space is needed.
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
		$
Schedule B (Form 990, 990-EZ, or 990-PF) (2012)

Schedule B (Form 990, 990-EZ, or 990-PF) (2012)

Page 4

Name of organization
THE MICHAEL J FOX FOUNDATION
FOR PARKINSON'S RESEARCH

Employer identification number

13-4141945

Part III

Exclusively religious, charitable, etc., individual contributions to section 501(c)(7), (8), or (10) organizations
that total more than $1,000 for the year. Complete columns (a) through (e) and the following line entry.
For organizations completing Part III, enter the total of exclusively religious, charitable, etc.,
contributions of $1,000 or less for the year. (Enter this information once. See instructions.) Arrow Bullet

$
Use duplicate copies of Part III if additional space is needed.

(a) No.
from
Part I

(b) Purpose of gift

(d) Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

(a) No.
from
Part I

(b) Purpose of gift

(d) Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

(a) No.
from
Part I

(b) Purpose of gift

(d) Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

(a) No.
from
Part I

(b) Purpose of gift

(d) Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

Schedule B (Form 990, 990-EZ, or 990-PF) (2012)

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE D
(Form 990)

Department of the Treasury
Internal Revenue Service

Supplemental Financial Statements

Complete if the organization answered "Yes," to Form 990,
Part IV, line 6, 7, 8, 9, 10, 11a, 11b, 11c, 11d, 11e, 11f, 12a, or 12b
SchDMd Bullet

Attach to Form 990. SchDMd Bullet

See separate instructions.

OMB No. 1545-0047

2012

Open to Public Inspection

Name of the organization

THE MICHAEL J FOX FOUNDATION
FOR PARKINSON'S RESEARCH

Employer identification number

13-4141945

Part I

Organizations Maintaining Donor Advised Funds or Other Similar Funds or Accounts. Complete if the organization answered "Yes" to Form 990, Part IV, line 6.

		(a) Donor advised funds	(b) Funds and other accounts
1	Total number at end of year .........
2	Aggregate contributions to (during year) ...
3	Aggregate grants from (during year) .....
4	Aggregate value at end of year ........

Did the organization inform all donors and donor advisors in writing that the assets held in donor advised
funds are the organization's property, subject to the organization's exclusive legal control? ............

Yes No

Did the organization inform all grantees, donors, and donor advisors in writing that grant funds can be
used only for charitable purposes and not for the benefit of the donor or donor advisor, or for any other purpose conferring impermissible private benefit? ...................................

Yes No

Part II

Conservation Easements. Complete if the organization answered "Yes" to Form 990, Part IV, line 7.

Purpose(s) of conservation easements held by the organization (check all that apply).

Preservation of land for public use (e.g., recreation or education) Preservation of an historically important land area

Protection of natural habitat Preservation of a certified historic structure

Preservation of open space

Complete lines 2a through 2d if the organization held a qualified conservation contribution in the form of a conservation easement on the last day of the tax year.


a	Total number of conservation easements .......................	2a
b	Total acreage restricted by conservation easements ..................	2b
c	Number of conservation easements on a certified historic structure included in (a) .....	2c
d	Number of conservation easements included in (c) acquired after 8/17/06, and not on a historic structure listed in the National Register ....................	2d

Number of conservation easements modified, transferred, released, extinguished, or terminated by the organization during
the tax year SchDMd Bullet

Number of states where property subject to conservation easement is located SchDMd Bullet

Does the organization have a written policy regarding the periodic monitoring, inspection, handling of violations, and
enforcement of the conservation easements it holds? .............................

Yes No

Staff and volunteer hours devoted to monitoring, inspecting, and enforcing conservation easements during the year
SchDMd Bullet

Amount of expenses incurred in monitoring, inspecting, and enforcing conservation easements during the year
SchDMd Bullet

Does each conservation easement reported on line 2(d) above satisfy the requirements of section 170(h)(4)(B)(i) and section 170(h)(4)(B)(ii)? .......................................

Yes No

In Part XIII, describe how the organization reports conservation easements in its revenue and expense statement, and
balance sheet, and include, if applicable, the text of the footnote to the organization’s financial statements that describes
the organization’s accounting for conservation easements.

Part III

Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets.
Complete if the organization answered "Yes" to Form 990, Part IV, line 8.

If the organization elected, as permitted under SFAS 116 (ASC 958), not to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service, provide, in Part XIII, the text of the footnote to its financial statements that describes these items.

If the organization elected, as permitted under SFAS 116 (ASC 958), to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service, provide the following amounts relating to these items:

(i)

Revenues included in Form 990, Part VIII, line 1 ........................ SchDMd Bullet

(ii)

Assets included in Form 990, Part X .............................. SchDMd Bullet

If the organization received or held works of art, historical treasures, or other similar assets for financial gain, provide the
following amounts required to be reported under SFAS 116 (ASC 958) relating to these items:

Revenues included in Form 990, Part VIII, line 1 .......................... SchDMd Bullet

Assets included in Form 990, Part X ............................... SchDMd Bullet

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 52283D

Schedule D (Form 990) 2012

Page 2

Part III

Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets (continued)

Using the organization’s acquisition, accession, and other records, check any of the following that are a significant use of its collection items (check all that apply):

Public exhibition

Loan or exchange programs

Scholarly research

Other

Preservation for future generations

Provide a description of the organization’s collections and explain how they further the organization’s exempt purpose in
Part XIII.

During the year, did the organization solicit or receive donations of art, historical treasures or other similar
assets to be sold to raise funds rather than to be maintained as part of the organization’s collection?........

Yes No

Part IV

Escrow and Custodial Arrangements. Complete if the organization answered "Yes" to Form 990,
Part IV, line 9, or reported an amount on Form 990, Part X, line 21.

Is the organization an agent, trustee, custodian or other intermediary for contributions or other assets not
included on Form 990, Part X? ....................................

Yes No

If "Yes," explain the arrangement in Part XIII and complete the following table:


c	Beginning balance .................................	1c
d	Additions during the year ..............................	1d
e	Distributions during the year .............................	1e
f	Ending balance ...................................	1f

Did the organization include an amount on Form 990, Part X, line 21? .....................

Yes No

If “Yes,” explain the arrangement in Part XIII. Check here if the explanation has been provided in Part XIII ........

Part V

Endowment Funds. Complete if the organization answered "Yes" to Form 990, Part IV, line 10.

		(a)Current year	(b)Prior year	b (c)Two years back	(d)Three years back	(e)Four years back
1a	Beginning of year balance ....
b	Contributions ........
c	Net investment earnings, gains, and losses
d	Grants or scholarships .....
e	Other expenditures for facilities and programs ........
f	Administrative expenses ....
g	End of year balance ......

Provide the estimated percentage of the current year end balance (line 1g, column (a)) held as:

Board designated or quasi-endowment SchDMd Bullet

Permanent endowment SchDMd Bullet

Temporarily restricted endowment SchDMd Bullet

The percentages in lines 2a, 2b, and 2c should equal 100%.

Are there endowment funds not in the possession of the organization that are held and administered for the
organization by:

Yes

(i) unrelated organizations ........................

3a(i)

(ii) related organizations ........................

3a(ii)

If "Yes" to 3a(ii), are the related organizations listed as required on Schedule R? .........

Describe in Part XIII the intended uses of the organization's endowment funds.

Part VI

Land, Buildings, and Equipment. See Form 990, Part X, line 10.

Description of property		(b)Cost or other basis (other)	(c) Accumulated depreciation	(d) Book value
1a	Land .................
b	Buildings ................
c	Leasehold improvements ............	1,692,761	407,395	1,285,366
d	Equipment ................	1,887,019	1,069,253	817,766
e	Other .................	252,692	211,435	41,257
Total. Add lines 1a through 1e. (Column (d) must equal Form 990, Part X, column (B), line 10(c).).......				2,144,389

Schedule D (Form 990) 2012

Page 3

Part VII

InvestmentsOther Securities. See Form 990, Part X, line 12.

(a) Description of security or category (including name of security)		(b)Book value	(c) Method of valuation: Cost or end-of-year market value
(1)Financial derivatives
(2)Closely-held equity interests
Other








Total. (Column (b) must equal Form 990, Part X, col. (B) line 12.)

Part VIII

InvestmentsProgram Related. See Form 990, Part X, line 13.

(a) Description of investment type		(b) Book value	(c) Method of valuation: Cost or end-of-year market value









Total. (Column (b) must equal Form 990, Part X, col.(B) line 13.)

Part IX

Other Assets. See Form 990, Part X, line 15.

(a) Description				(b) Book value









Total. (Column (b) must equal Form 990, Part X, col.(B) line 15.)...........

Part X

Other Liabilities. See Form 990, Part X, line 25.

1.(a) Description of liability		(b) Book value
Federal income taxes		0
DEFERRED RENT		897,274
DUE TO MJFF CANADA		105,926
INTEREST PAYABLE		215,395






Total. (Column (b) must equal Form 990, Part X, col.(B) line 25.)		1,218,595
2. Fin 48 (ASC 740) Footnote. In Part XIII, provide the text of the footnote to the organization's financial statements that reports the organization's liability for uncertain tax positions under FIN 48 (ASC 740). Check here if the text of the footnote has been provided in Part XIII .....................................................

Schedule D (Form 990) 2012

Page 4

Part XI Reconciliation of Revenue per Audited Financial Statements With Revenue per Return
1	Total revenue, gains, and other support per audited financial statements .......			1	87,836,044
2	Amounts included on line 1 but not on Form 990, Part VIII, line 12:
a	Net unrealized gains on investments ..........	2a	6,394
b	Donated services and use of facilities .........	2b
c	Recoveries of prior year grants ...........	2c
d	Other (Describe in Part XIII.) ............	2d	293,559
e	Add lines 2a through 2d .....................			2e	299,953
3	Subtract line 2e from line 1.....................			3	87,536,091
4	Amounts included on Form 990, Part VIII, line 12, but not on line 1:
a	Investment expenses not included on Form 990, Part VIII, line 7b .	4a
b	Other (Describe in Part XIII.) ...........	4b
c	Add lines 4a and 4b.......................			4c
5	Total revenue. Add lines 3 and 4c. (This must equal Form 990, Part I, line 12.) ......			5	87,536,091

Part XII Reconciliation of Expenses per Audited Financial Statements With Expenses per Return
1	Total expenses and losses per audited financial statements ...........			1	70,540,350
2	Amounts included on line 1 but not on Form 990, Part IX, line 25:
a	Donated services and use of facilities ..........	2a
b	Prior year adjustments ..............	2b
c	Other losses ................	2c
d	Other (Describe in Part XIII.) ............	2d	293,559
e	Add lines 2a through 2d......................			2e	293,559
3	Subtract line 2e from line 1.....................			3	70,246,791
4	Amounts included on Form 990, Part IX, line 25, but not on line 1:
a	Investment expenses not included on Form 990, Part VIII, line 7b ..	4a
b	Other (Describe in Part XIII.) ............	4b
c	Add lines 4a and 4b.......................			4c
5	Total expenses. Add lines 3 and 4c. (This must equal Form 990, Part I, line 18.) ......			5	70,246,791

Part XIII

Supplemental Information

Complete this part to provide the descriptions required for Part II, lines 3, 5, and 9; Part III, lines 1a and 4; Part lV, lines 1b and 2b;
Part V, line 4; Part X, line 2; Part XI, lines 2d and 4b; and Part XII, lines 2d and 4b. Also complete this part to provide any additional information.

Identifier	Return Reference	Explanation
Schedule D, Page 3, Question 2:	ASC 740-10-05 Footnote	The Foundation is subject to the provisions of the Financial Accounting Standards Board's Accounting Standards Codification ("ASC") Topic 740-10-05 relating to accounting and reporting for uncertainty in income taxes. For the Foundation, ASC Topic 740-10-05 is potentially applicable to the incurrence of unrelated business income ("UBIT") attributable to certain of the Foundation's merchandise sales. Nonetheless, because of Foundation's general tax-exempt status, ASC Topic 740-10-05 has not had, and is not expected to have, a material impact on the Foundation's financial statements.
RECONCILIATION OF REVENUE AND EXPENSES	SCHEDULE D, PARTS XII/XIII, LINES 2D, PAGE 4	AMOUNTS REPRESENT REVENUES AND EXPENSES ATTRIBUTABLE TO THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH'S CANADIAN ENTITY.

Schedule D (Form 990) 2012

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE F(Form 990)

Department of the Treasury
Internal Revenue Service

Statement of Activities Outside the United States

Complete if the organization answered "Yes" to Form 990,Part IV, line 14b, 15, or 16. Right pointing arrow large image

Attach to Form 990. Right pointing arrow large image

See separate instructions.

OMB No. 1545-0047

2012

Open to Public Inspection

Name of the organization
THE MICHAEL J FOX FOUNDATION
FOR PARKINSON'S RESEARCH

Employer identification number

13-4141945

Part I

General Information on Activities Outside the United States. Complete if the organization answered “Yes” to Form 990, Part IV, line 14b.

For grantmakers. Does the organization maintain records to substantiate the amount of the grants or

assistance, the grantees’ eligibility for the grants or assistance, and the selection criteria used to award

the grants or assistance? ...................................

Yes

For grantmakers. Describe in Part V the organization’s procedures for monitoring the use of grant funds outside
the United States.

Activites per Region. (The following Part I, line 3 table can be duplicated if additional space is needed.)

(a) Region		(d) Activities conducted in region (by type) (e.g., fundraising, program services, investments, grants to recipients located in the region)	(f) Total expenditures for and investments in region
	East Asia and the Pacific	Grantmaking	1,535,455
	North America	Grantmaking	4,400,327
	Europe (Including Iceland and Greenland)	Grantmaking	10,285,793
	Middle East and North Africa	Grantmaking	946,623
	South America	Grantmaking	86,300












3a	Sub-total .....		17,254,498
b	Total from continuation sheets to Part I ...
c	Totals (add lines 3a and 3b)		17,254,498

For Paperwork Reduction Act Notice, see the Instructions for Form 990.Cat. No. 50082W Schedule F (Form 990) 2012

Schedule F (Form 990) 2012

Page 2

Part II

Grants and Other Assistance to Organizations or Entities Outside the United States. Complete if the organization answered “Yes” to Form 990, Part IV, line 15, for any recipient who received more than $5,000. Part II can be duplicated if additional space is needed.

(c) Region	(d) Purpose of grant	(e) Amount of cash grant
Europe (Including Iceland and Greenland)	Xenon inhalation to reduce L-DOPA-induced dyskinesia	461,577
North America	Development of a non-human primate model of Parkinson's disease alpha-synucleinopathy	502,882
Europe (Including Iceland and Greenland)	Modulation of the CD40/CD40-Ligand Neuroinflammation Pathway in Parkinson's Mouse Models	74,966
Europe (Including Iceland and Greenland)	Development of an HTS assay to break the alpha- synuclein-glucocerebrosidase feedback loop	74,250
Europe (Including Iceland and Greenland)	Small molecule screening for a-synuclein binders using Surface Plasmon Resonance (SPR). Fluorescence and radiometric competition binding assays for identification of compounds selectively binding to a-synuclein	947,290
Europe (Including Iceland and Greenland)	Enhanced CNS dopamine availability, prolonged activity and improved dyskinesia profile after administration of selectively deuterated L-DOPA	400,000
East Asia and the Pacific	Is the xenomitochondrial mouse an 'ideal' PD model?	36,726
North America	Mechanisms of Parkin Recruitment and Mitophagy	199,990
North America	A Two-dose Active Comparator, Randomized Cross- over Phase I Trial to Examine the Single Dose Pharmacokinetic Profile of Sublingual Administered APL-130277 as compared to APOKYN in Healthy Volunteers	947,925
East Asia and the Pacific	Collaborative validation of oxidized DJ-1 antibodies for PD biomarker study	203,655
Europe (Including Iceland and Greenland)	In vivo characterization of helper-dependent adenoviral vectors expressing human LRRK2	112,163
Europe (Including Iceland and Greenland)	Regulation of LRRK2 Activity and Toxicity by Nitrosative Stress and S-Nitrosylation: Implications for Idiopathic Parkinson's Disease	133,474
Europe (Including Iceland and Greenland)	Novel PD Tools: Generation of Post- translationally Modified Alpha-synuclein	233,526
Europe (Including Iceland and Greenland)	VPS35 as a Novel Target for Parkinson's Disease	249,806
Europe (Including Iceland and Greenland)	Investigation of the mechanisms involved in a-synuclein secretion in vivo	150,000
East Asia and the Pacific	Validation of ATP13a2/PARK9 as a Target to Reduce Neurodegeneration Induced by Alpha-Synuclein	249,657
Europe (Including Iceland and Greenland)	Enhancing PD symptom improvement and decreasing adverse event incidence from L-DOPA therapy by improving L-DOPA bioavailability and consistency of absorption through co-administration of the Motilin agonist, GSK962040	78,410
Europe (Including Iceland and Greenland)	Anti-parkinson and anti-dyskinetic efficacy studies of HE3286 in a MPTP non-human primate model for Parkinson's disease	431,528
Europe (Including Iceland and Greenland)	Protein Interaction network analysis and pathway modeling for LRRK2	1,499,839
Europe (Including Iceland and Greenland)	Intestinal and nasal microbiota of patients with idiopathic Parkinson's disease	75,000
Europe (Including Iceland and Greenland)	PPMI 2012: RBD Core Support for Prodromal PPMI (P-PPMI) in 2013	130,000
Europe (Including Iceland and Greenland)	PPMI 2012: Cognitive Categorization Ancillary Study	14,063
Europe (Including Iceland and Greenland)	Is PD a low-grade inflammatory bowel disease?	52,910
Europe (Including Iceland and Greenland)	IMD-026259 - An Innovative Drug for Disease- Modifying Treatment of Parkinson's Disease	499,989
Europe (Including Iceland and Greenland)	Cognitive phenotypes in Parkinson's disease: anatomical and functional correlates	366,025
Europe (Including Iceland and Greenland)	The role of mGluR4 in the modulation of L-DOPA- induced motor performance and dyskinesia in a rat model of Parkinson's disease - 2012	35,689
Europe (Including Iceland and Greenland)	Neurotrophic and autophagic markers in Parkinson's disease: Implications for disease- modifying strategies	60,000
Europe (Including Iceland and Greenland)	Functional Integration of Grafted Human Induced Neuronal (iN) Cells in Parkinson's Disease	74,951
Europe (Including Iceland and Greenland)	Validation of IGF-1 as a neuroprotective agent in animal models of Parkinson?s disease	110,000
Europe (Including Iceland and Greenland)	Preclinical validation of a Nurr1 agonist for neuroprotection in Parkinson's disease	115,500
Europe (Including Iceland and Greenland)	Transfer of alpha-synuclein between the brain and peripheral organs	200,000
Europe (Including Iceland and Greenland)	Regulated GDNF gene therapy- a novel regulatory system based on protein degradation.	219,451
Europe (Including Iceland and Greenland)	PDGene Extension	58,307
North America	Stimulation of protein clearance mechanisms to improve clearance of toxic accumulations of alpha-synuclein protein in Parkinson's disease	75,000
Europe (Including Iceland and Greenland)	PPMI 2012: rsMRI Ancillary Study	9,688
Europe (Including Iceland and Greenland)	PPMI 2012: Cognitive Categorization Ancillary Study	11,250
Europe (Including Iceland and Greenland)	Laboratory phenotyping of Parkinson disease subjects using a multiplex approach	222,023
Europe (Including Iceland and Greenland)	PPMI Clinical Trial Site: Year Two	258,781
Europe (Including Iceland and Greenland)	The role of brain-specific PGC-1alpha isoforms in Parkinson Disease	75,000
Europe (Including Iceland and Greenland)	Clinical Coordination of LRRK2 Cohort Consortium- Supplement	24,259
Europe (Including Iceland and Greenland)	Lead optimization for a Parkinson's Disease therapeutic	399,894
Europe (Including Iceland and Greenland)	Trace amines and their metabolites as potential heraldic markers in Parkinson's disease	74,986
Europe (Including Iceland and Greenland)	PPMI Clinical Trial Site - SWEDD Amendment	59,438
Europe (Including Iceland and Greenland)	Ceruloplasmin deamidation in Parkinson's disease cerebrospinal fluid: gain of pro-adhesive function	73,150
North America	Sanofi Packaging and distribution project	19,467
Middle East and North Africa	LRRK2 Cohort Consortium Biorepository Agreement- Tel Aviv	946,623
Europe (Including Iceland and Greenland)	Attenuation of neuroinflammation by brain- targeted liposomal methylprednisolone (2B3-201)	75,000
Europe (Including Iceland and Greenland)	Characterizing region specific splice isoforms of LRRK2	124,935
Europe (Including Iceland and Greenland)	Cannabinoid CB2 receptors as a new target for the treatment of disease progression in Parkinson's disease: studies in LRRK2-transgenic mice	146,258
North America	Development of L-745,870, a selective D4 receptor antagonist, for the treatment of L-DOPA-induced dyskinesia	1,086,711
Europe (Including Iceland and Greenland)	CD163+ macrophages as tools for neuroinflammatory modulation in Parkinson's disease	74,745
Europe (Including Iceland and Greenland)	Cleaved Cerebrospinal Fluid Proteins as Early Biomarkers for Detection of Parkinson's Disease	92,640
North America	Investigation of neuroinflammation in LRRK2 mutation carriers using positron emission tomography	249,947
North America	Imaging Neuroinflammation in LRRK2 Rat Models of Parkinson's Disease	296,533
North America	Pharmacological targeting of the 5-HT1, A2A and NMDA receptors: an integrative approach to dyskinesia	389,400
South America	Targeting the unfolded protein response transcription factor XBP1 to alleviate neurodegeneration triggered by alpha-synuclein.	86,300
East Asia and the Pacific	LRRK2 HD-AD5 Subcloning work	9,468
East Asia and the Pacific	Generation of phospho-PINK1 and phospho-Parkin Antibodies	18,553
East Asia and the Pacific	Combining mass spectrometry with genetic and pharmacological approaches to discover and validate LRRK2 substrates	1,500,057
Europe (Including Iceland and Greenland)	Effects of recombinant CDNF protein in alpha- synuclein model of Parkinson's disease in rats	125,000
Europe (Including Iceland and Greenland)	PPMI 2012: Cognitive Categorization Ancillary Study	7,969
Europe (Including Iceland and Greenland)	PPMI 2012: rsMRI Ancillary Study	9,688
East Asia and the Pacific	Alpha synuclein as a major regulator of iron homeostasis	62,203
North America	LRRK2 regulates host response to microbial infections	250,000
East Asia and the Pacific	Evaluating a targeted cognitive training program for the treatment of Freezing of Gait	490,663
North America	A novel protease pathway in Parkinson's disease	74,586
North America	Biomarkers of PD risk in LRRK2 mutation carriers	466,755
North America	Validation of Sirtuin 3 as a Neuroprotective Target in Parkinson's Disease	250,000
Europe (Including Iceland and Greenland)	PPMI 2012: rsMRI Ancillary Study	9,688
Europe (Including Iceland and Greenland)	PPMI 2012: Cognitive Categorization Ancillary Study	15,469
Europe (Including Iceland and Greenland)	Polyglutamine repeats and Parkinson disease	74,800

Enter total number of recipient organizations listed above that are recognized as charities by the foreign country, recognized as tax-exempt by the IRS, or for which the grantee or counsel has provided a section 501(c)(3) equivalency letter .... MediumBullet

Enter total number of other organizations or entities ....................... MediumBullet

Schedule F (Form 990) 2012

Schedule F (Form 990) 2012Page 3

Part III

Grants and Other Assistance to Individuals Outside the United States. Complete if the organization answered "Yes" to Form 990, Part IV, line 16.

Part III can be duplicated if additional space is needed.

(a) Type of grant or assistance		(b) Region	(c) Number of recipients	(d) Amount of cash grant	(e) Manner of cash disbursement	(f) Amount of non-cash assistance	(g) Description of non-cash assistance	(h) Method of valuation (book, FMV, appraisal, other)

Schedule F (Form 990) 2012

Page 4

Part IV

Foreign Forms

Schedule F (Form 990) 2012

Page 5

Part V

Supplemental Information
Complete this part to provide the information required by Part I, line 2 (monitoring of funds); Part I, line 3, column (f) (accounting method; amounts of investments vs. expenditures per region); Part II, line 1 (accounting method); Part III (accounting method); and Part III, column (c) (estimated number of recipients), as applicable. Also complete this part to provide any additional information (see instructions).

Identifier	ReturnReference	Explanation
SCHEDULE F	PROCEDURES FOR MONITORING GRANT FUNDS OUTSIDE THE UNITED STATES:	THE FOUNDATION AWARDS RESEARCH GRANTS BASED UPON THE GUIDANCE AND INPUT OF THE SCIENTIFIC ADVISORY BOARD AND OTHER HIGHLY REGARDED SCIENTISTS WHO SERVE ON GRANT REVIEW COMMITTEES SPECIALIZING IN PARKINSON'S RESEARCH. Goals and milestones are described within each grant award. Most Grant awards are allocated in multiple payments with key benchmarks set at the time of the grant award. MJFF's Research team closely monitors the progress of each grant awarded. There is frequent communication between grantees and MJFF staff regarding the progress of each grant. Progress is verified before additional payments are made.

Schedule F (Form 990) 2012

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE G (Form 990 or 990-EZ)

Department of the Treasury
Internal Revenue Service

Supplemental Information Regarding
Fundraising or Gaming Activities

Complete if the organization answered "Yes" to Form 990, Part IV, lines 17, 18, or 19, or if the organization entered more than $15,000 on Form 990-EZ, line 6a. Form 990-EZ filers are not required to complete this part. right arrow

Attach to Form 990 or Form 990-EZ. right arrow

See separate instructions.

OMB No. 1545-0047

2012

Open to Public Inspection

Name of the organization
THE MICHAEL J FOX FOUNDATION
FOR PARKINSON'S RESEARCH

Employer identification number

13-4141945

Part I

Fundraising Activities. Complete if the organization answered "Yes" to Form 990, Part IV, line 17.

Indicate whether the organization raised funds through any of the following activities. Check all that apply.

a	Mail solicitations	e	Solicitation of non-government grants
b	Internet and email solicitations	f	Solicitation of government grants
c	Phone solicitations	g	Special fundraising events
d	In-person solicitations

Did the organization have a written or oral agreement with any individual (including officers, directors, trustees

or key employees listed in Form 990, Part VII) or entity in connection with professional fundraising services?

Yes

If “Yes,” list the ten highest paid individuals or entities (fundraisers) pursuant to agreements under which the fundraiser is
to be compensated at least $5,000 by the organization.

(i) Name and address of individual or entity (fundraiser)		(ii) Activity	(iii) Did fundraiser have custody or control of contributions?		(iv) Gross receipts from activity	(v) Amount paid to (or retained by) fundraiser listed in col. (i)	(vi) Amount paid to (or retained by) organization
			Yes	No
	Event Associates Inc	Fundraising Consulting		No	0	60,000	0









Total .................					0	60,000	0

List all states in which the organization is registered or licensed to solicit funds or has been notified it is exempt from registration or licensing.

AL, AK, AZ, AR, CA, CO, CT, FL, GA, IL, KS, KY, ME, MD, MA, MI, MN, MS, NH, NJ, NM, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, UT, VA, WA, WV, WI

For Paperwork Reduction Act Notice, see the Instructions for Form 990or 990-EZ.

Cat. No. 50083H

Schedule G (Form 990 or 990-EZ) 2012

Page 2

Part II

Fundraising Events. Complete if the organization answered "Yes" to Form 990, Part IV, line 18, or reported more than $15,000 of fundraising event contributions and gross income on Form 990-EZ, lines 1 and 6b. List events with gross receipts greater than $5,000.

		(a) Event #1 FUNNY THING (event type)	(b) Event #2 BREAKING PAR (event type)	(c) Other events 3 (total number)	(d) Total events (add col. (a) through col. (c))
1	Gross receipts . . .	4,225,532	614,840	602,825	5,443,197
2	Less: Contributions . .	3,520,856	489,652	519,294	4,529,802
3	Gross income (line 1 minus line 2) . . .	704,676	125,188	83,531	913,395
4	Cash prizes . . .	0	0	0	0
5	Noncash prizes . .	0	0	3,263	3,263
6	Rent/facility costs . .	447,540	107,838	60,858	616,236
7	Food and beverages .	0	0	0	0
8	Entertainment . . .	238,355		16,471	254,826
9	Other direct expenses .	18,780	17,350	2,940	39,070
10	Direct expense summary. Add lines 4 through 9 in column (d) ...........				913,395
11	Net income summary. Combine line 3, column (d), and line 10. ..........

Part III

Gaming. Complete if the organization answered "Yes" to Form 990, Part IV, line 19, or reported more than $15,000 on Form 990-EZ, line 6a.

(a) Bingo

(b) Pull tabs/Instant
bingo/progressive bingo

(c) Other gaming

(d) Total gaming (add col.(a) through col.(c))

Gross revenue . . . .

Cash prizes . . . .

Non-cash prizes . . .

Rent/facility costs . . .

Other direct expenses . .

Volunteer labor . . .

	Yes
	No

	Yes
	No

	Yes
	No

Direct expense summary. Add lines 2 through 5 in column (d) ........... right arrow

Net gaming income summary. Combine lines 1 and 7 in column (d) .......... right arrow

Enter the state(s) in which the organization operates gaming activities:

Is the organization licensed to operate gaming activities in each of these states? ............

YesNo

If "No," explain:

10a

Were any of the organization's gaming licenses revoked, suspended or terminated during the tax year? .....

YesNo

If "Yes," explain:

Schedule G (Form 990 or 990-EZ) 2012

Page 3

Does the organization operate gaming activities with nonmembers? .................

YesNo

Is the organization a grantor, beneficiary or trustee of a trust or a member of a partnership or other entity

formed to administer charitable gaming? ..........................

YesNo

Indicate the percentage of gaming activity operated in:

The organization's facility ......................

13a

An outside facility ........................

13b

Enter the name and address of the person who prepares the organization's gaming/special events books and records:

Name

Address

15a

Does the organization have a contract with a third party from whom the organization receives gaming

revenue? ......................................

YesNo

If "Yes," enter the amount of gaming revenue received by the organization right arrow

$ and the

amount of gaming revenue retained by the third party right arrow

$ .

If "Yes," enter name and address of the third party:

Name

Address

Gaming manager information:

Name

Gaming manager compensation right arrow

Description of services provided right arrow

Director/officer Employee Independent contractor

Mandatory distributions:

Is the organization required under state law to make charitable distributions from the gaming proceeds to

retain the state gaming license? ............................

YesNo

Enter the amount of distributions required under state law distributed to other exempt organizations or spent

in the organization's own exempt activities during the tax year right arrow

Part IV

Supplemental Information. Complete this part to provide the explanations required by Part I, line 2b, columns (iii) and (v), and Part III, lines 9, 9b, 10b, 15b, 15c, 16, and 17b, as applicable. Also complete this part to provide any additional information (see instructions).

Identifier	Return Reference	Explanation

Schedule G (Form 990 or 990-EZ) 2012

Additional Data

Software ID:
Software Version:

- TIN:

Schedule I
(Form 990)

Department of the Treasury
Internal Revenue Service

Grants and Other Assistance to Organizations,
Governments and Individuals in the United States

Complete if the organization answered "Yes," to Form 990, Part IV, line 21 or 22.
lBullet

Attach to Form 990

OMB No. 1545-0047

2012

Open to Public
Inspection

Name of the organization
THE MICHAEL J FOX FOUNDATION
FOR PARKINSON'S RESEARCH

Employer identification number
13-4141945

Part I

General Information on Grants and Assistance

Does the organization maintain records to substantiate the amount of the grants or assistance, the grantees' eligibility for the grants or assistance, and
the selection criteria used to award the grants or assistance? ....................................

Yes No

Describe in Part IV the organization's procedures for monitoring the use of grant funds in the United States.

Part II

Grants and Other Assistance to Governments and Organizations in the United States. Complete if the organization answered "Yes" to
Form 990, Part IV, line 21, for any recipient that received more than $5,000. Part II can be duplicated if additional space is needed.

(a) Name and address of organization or government	(b) EIN	(c) IRC Code section if applicable	(d) Amount of cash grant	(h) Purpose of grant or assistance
(1) 23andMe Inc 2606 Bayshore Parkway Mountain View,CA94043	20-4857371	Public Sector	26,400	Using external research experts to mine the 23andMe Parkinson's dataset
(2) 23andMe Inc 2606 Bayshore Parkway Mountain View,CA94043	20-4857371	Public Sector	291,428	23andMe Blood Collection for the LRRK2 Consortium
(3) Acadia Pharmaceuticals 3911 Sorrento Valley Blvd San Diego,CA92121	06-1376651	Public Sector	322,414	Development of Nurr1-RXR heterodimer selective agonists for Parkinson's disease
(4) Alnylam Pharmaceuticals 300 Third Street Cambridge,MA02142	77-0602661	Public Sector	25,000	Therapeutic Development of siRNA Targeting Alpha-Synuclein
(5) Alnylam Pharmaceuticals 300 Third Street Cambridge,MA02142	77-0602661	Public Sector	162,668	Therapeutic Development of siRNA Targeting Alpha-Synuclein
(6) Aperio Technologies 1360 Park Center Drive Vista,CA92081	33-0939292	Public Sector	10,530	Aperio Website Hosting of Immunohistological Slides -LRRK2
(7) Avanir Pharmaceuticals 20 Enterprise Orange,CA92121	33-0314804	Public Sector	569,151	AVP-923 (dextromethorphan hydrobromide and quinidine sulfate) for levodopa induced dyskinesia in Parkinson's disease
(8) Banner Sun Health Research Institute 10515 W Santa Fe Drive Sun City,AZ85351	86-0768795	501(c)(3)	8,438	PPMI 2012: Cognitive Categorization Ancillary Study
(9) Banner Sun Health Research Institute 10515 W Santa Fe Drive Sun City,AZ85351	86-0768795	501(c)(3)	15,000	APDC Reviewer compensation
(10) Banner Sun Health Research Institute 10515 W Santa Fe Drive Sun City,AZ85351	86-0768795	501(c)(3)	50,000	AV-133: PPMI Ancillary Study
(11) Baylor College of Medicine 6550 Fannin St Suite 1801 Houston,TX77030	74-1613878	501(c)(3)	9,688	PPMI 2012: rsMRI Ancillary
(12) Baylor College of Medicine 6550 Fannin St Suite 1801 Houston,TX77030	74-1613878	501(c)(3)	13,125	PPMI 2012: Cognitive Categorization Ancillary Study
(13) Baylor College of Medicine One Baylor Plaza Room 630E Houston,TX77030	74-1613878	501(c)(3)	45,000	Generation of HD-Ad Type 5 LRRK2 expression vectors
(14) Baylor College of Medicine 6550 Fannin St Suite 1801 Houston,TX77030	74-1613878	501(c)(3)	50,000	AV-133: PPMI Ancillary Study
(15) Beth Israel Deaconess Medical Center 330 Brookline Ave Room CLS-638 Boston,MA02445	04-2103881	501(c)(3)	75,000	Irisin: A novel PGC-1alpha related target for neuroprotection in Parkinson's Disease
(16) Beth Israel Medical Center 10 Union Square East Suite 2Q New York,NY10003	13-5564934	501(c)(3)	142,156	Planning Phase for LARRI
(17) Beth Israel Medical Center 10 Union Square East PACC Suite 5 New York,NY10003	13-5564934	501(c)(3)	509,385	LRRK2 Mutations and Cancer Risk
(18) Biomer Technology 1047 Serpentine Lane Bldg 200 Pleasantown,CA94566	48-1286101	Public Sector	62,000	Post-Translationally Modified Alpha-Synuclein: Generation and Ligation of modified Peptides to Alpha-Synuclein Protein
(19) Board of Regents of the University of Wisconsin 600 Highland Ave K4/7 CSC Madison,WI53792	39-6006492	501(c)(3)	79,955	Characterization of vocalization and swallowing deficits in Pink1 knockout rats
(20) Boston University Robinson C-329 715 Albany St Boston,MA02118	04-2103545	501(c)(3)	12,656	PPMI 2012: Cognitive Categorization Ancillary Study
(21) Boston University Robinson C-329 715 Albany St Boston,MA02118	04-2103545	501(c)(3)	137,500	PPMI Clinical Trial Site: Year Two
(22) Boston University Robinson C-329 715 Albany St Boston,MA02118	04-2103545	501(c)(3)	150,000	PPMI Clinical Trial Site: Year Three
(23) Boston University 72 East Concord St L-606B Boston,MA02118	04-2103545	501(c)(3)	274,219	Clinical evaluation of LRRK2 inhibitors on inflammatory responses in Crohn's and Parkinson's diseases
(24) Brigham & Women's Hospital 65 Landsdowne Street Boston,MA02139	04-2312909	501(c)(3)	71,607	Evaluation of PD-linked transcripts in PPMI
(25) City College of New York 1230 York Avenue Box 296 New York,NY10065	13-1624158	501(c)(3)	147,301	The Role of CK2 in the development of L-DOPA- induced dyskinesia in Parkinson's disease
(26) Cleveland Clinic 9500 Euclid Avenue S-31 Cleveland,OH44195	34-0714585	501(c)(3)	9,688	PPMI 2012: rsMRI Ancillary Study
(27) Cleveland Clinic 9500 Euclid Avenue S-31 Cleveland,OH44195	34-0714585	501(c)(3)	12,188	PPMI 2012: Cognitive Categorization Ancillary Study
(28) Colorado State University 1680 Campus Delivery Fort Collins,CO805231680	84-6000545	501(c)(3)	112,170	Targeting Nurr1 with novel diindolymethane compounds
(29) Columbia University 710 W168th St 3rd floor New York,NY10032	13-5598093	501(c)(3)	112,500	BioFIND Clinical Trial Site- Columbia University
(30) Coriell Institute for Medical Research 403 Haddon Avenue Camden,NJ08103	21-0672684	501(c)(3)	5,201	Collection, storage and distribution of MJFF samples from AVE8112 MAD study
(31) Coriell Institute for Medical Research 403 Haddon Avenue Camden,NJ08103	21-0672684	501(c)(3)	281,480	23andme LRRK2 Cohort Consortium Biorepository Agreement
(32) Coriell Institute for Medical Research 403 Haddon Avenue Camden,NJ08103	21-0672684	501(c)(3)	354,062	LRRK2 Cohort Consortium: Coriell Biorepository Supplement
(33) Coriell Institute for Medical Research 403 Haddon Avenue Camden,NJ08103	21-0672684	501(c)(3)	700,000	PPMI 2012: BioRepository Funding for 2012-2013
(34) Covance 180 Rustcraft Road Dedham,MA02026	22-3265977	Public Sector	26,480	RE-evaluation of the Qualification samples for DJ-1
(35) Covance 180 Rustcraft Road Dedham,MA02026	22-3265977	Public Sector	43,000	CSF Hemoglobin Assay
(36) Covance 180 Rustcraft Road Dedham,MA02026	22-3265977	Public Sector	65,751	PPMI 2012: Covance Funding for Australia Expansion
(37) Covance 180 Rustcraft Road Dedham,MA02026	22-3265977	Public Sector	137,500	Covance antibody testing, optimization and assay validation for Full Length LRRK2 P.O.# CAP08192012.
(38) DiaLean Ltd 675 US Highway One North Brunswick,NJ08902		Public Sector	205,996	DLN-101 for the treatment of Parkinson's Disease
(39) DNA 20 1140 OBrien Drive Suite A Menlo Park,CA94025	74-3076460	Public Sector	9,815	LRRK2 HD-Ad5
(40) Duke University CARL Bldg Research Dr Room 487 Durham,NC27710	56-0532129	501(c)(3)	125,000	Targeting beta-arrestin signaling in the treatment of Parkinson's disease
(41) East Tennessee State University PO Box 707577 Johnson City,TN37614	62-6021046	501(c)(3)	74,987	A genetic strategy to restore impaired noradrenergic function by increasing expression of noradrenergic phenotypes in the locus coeruleus in Parkinson's disease model mice
(42) Eli Lilly & Co Ltd XXXXX XXXXXX Indianapolis,IN46285	35-0470950	Public Sector	247,840	Identification of alpha-synuclein molecular forms correlating with clinicopathology of Parkinson's disease
(43) Emerald BioStructures 3 Preston Court Bedford,MA01730	91-1821586	Public Sector	1,343,780	LRRK2 Biological Structure and Function
(44) Emerald Print Management 1100 University Avenue Suite 142-B Rochester,NY14607	01-0803249	Public Sector	5,894	PPMI 2012: April Label Order #2
(45) Emerald Print Management 1100 University Avenue Suite 142-B Rochester,NY14607	01-0803249	Public Sector	6,785	PPMI 2012: April 2012 Label Order #1
(46) Emory University 1841 Clifton Road Third Floor Atlanta,GA30329	58-0566256	501(c)(3)	9,688	PPMI 2012: rsMRI Ancillary Study
(47) Emory University 1841 Clifton Road Third Floor Atlanta,GA30329	58-0566256	501(c)(3)	14,531	PPMI 2012: Cognitive Categorization Ancillary Study
(48) Emory University 1510 Clifton Rd Rm 3001 Atlanta,GA30322	58-0566256	501(c)(3)	25,000	Role of PARK18 in Parkinson's Disease
(49) Emory University 1841 Clifton Road Third Floor Atlanta,GA30329	58-0566256	501(c)(3)	155,000	PPMI Clinical Trial Site: Year Two
(50) Emory University 954 Gatewood Road NE Atlanta,GA30322	58-0566256	501(c)(3)	250,000	Antiparkinsonian effects of T-type calcium channel inhibitors
(51) Envoy Therapeutics 555 Heritage Drive Jupiter,FL33458	26-2535708	Public Sector	1,267,034	A New Mechanism for Highly Selective Modulation of the Indirect Pathway
(52) Epitomics 863 Mitten Road Suite 103 Burlingame,CA94010	94-3409030	Public Sector	6,727	Alpha-Synuclein S129 -- IgG cloning and batch production
(53) Epitomics 863 Mitten Road Suite 103 Burlingame,CA94010	94-3409030	Public Sector	6,727	LRRK1 IgG Cloning & Batch Production
(54) Epitomics 863 Mitten Road Suite 103 Burlingame,CA94010	94-3409030	Public Sector	8,361	Epitomics Antibodies for LRRK2 ELISA Development by Covance
(55) Epitomics 863 Mitten Road Suite 103 Burlingame,CA94010	94-3409030	Public Sector	13,454	pLRRK2 -- IgG Cloning Supplement for S955 and S97 3 Antibodies
(56) Epitomics 863 Mitten Road Suite 103 Burlingame,CA94010	94-3409030	Public Sector	31,802	LRRK2 PS1292 Antiobody Production
(57) Epitomics 863 Mitten Road Suite 103 Burlingame,CA94010	94-3409030	Public Sector	57,276	Phospho-Specific Antibody Generation
(58) Eureka Genomics 410 Pierce Street Suite 307 Houston,TX77002	26-1320502	Public Sector	19,975	Whole genome sequencing of LRRK2 mouse transgenic lines
(59) Feinstein Institute for Medical Research 350 Community Drive Research Build Manhasset,NY11030	11-2673595	501(c)(3)	578,941	Network Biomarkers for the Assessment of Parkinson's Disease: A Multi-modal Optimization Study
(60) FPRT Bio Inc PO Box 1335 Winthrop,WA98862	45-4804420	Public Sector	361,700	Peripheral administration of XPro1595 in the rat 6-OHDA model of Parkinson's disease
(61) Genentech 1 DNA Way South San Francisco,CA940804990	46-0500264	Public Sector	292,780	Non-human Primate Safety Study of LRRK2 Inhibitors cognitive disorders in Parkinson's disease
(62) Harvard University 243 Charles St Boston,MA02115	04-2103580	501(c)(3)	125,000	Non-Invasive Striatal Delivery of Glial Derived Neurotrophic Factor(GDNF) via a Novel Heterotopic Mucosal Grafting Technique
(63) Henry Ford Hospital 6777 West Maple Road Detroit,MI48322	38-1357020	501(c)(3)	147,093	Small-molecule PD biomarkers: a metabolomic analysis
(64) Indiana University 410 West Tenth Street HS 4000 Indianapolis,IN462023002	35-6001673	501(c)(3)	7,900	Aliquoting and shipping of DATATOP samples
(65) Indiana University 410 West Tenth Street HS 4000 Indianapolis,IN462023002	35-6001673	501(c)(3)	576,248	Consortium to Identify LRRK2 Modifiers of Age of Onset
(66) Johns Hopkins University 600 N Wolfe Street Meyer 6-119B Baltimore,MD21287	52-0595110	501(c)(3)	9,688	PPMI 2012: rsMRI Ancillary Study
(67) Johns Hopkins University 600 N Wolfe Street Meyer 6-119B Baltimore,MD21287	52-0595110	501(c)(3)	10,781	PPMI 2012: Cognitive Categorization Ancillary Study
(68) Johns Hopkins University 600 N Wolfe Street Meyer 6-119B Baltimore,MD21287	52-0595110	501(c)(3)	50,000	AV-133: PPMI Ancillary Study
(69) KineMed Inc 5980 Horton Street Suite 470 Emeryville,CA94608	91-2104596	Public Sector	1,190,319	Cross-sectional examination of cerebrospinal fluid kinetic biomarkers of axonal transport for Parkinson disease diagnosis and progression
(70) LZ Therapeutics Inc 490 Lapp Rd Malvern,PA19355	22-3930731	Public Sector	89,480	Evaluation of the Effects of Human Cell Derived GM1 Ganglioside in the MPTP Lesioned Mouse Model of Parkinson's Disease
(71) Massachusetts General Hospital 114 16th Street Room 2007 Boston,MA02129	04-2697983	501(c)(3)	137,896	Generation and characterization of iPS neurons from genetic Parkinson's Disease
(72) Massachusetts General Hospital Fruit Street WACC 715 Boston,MA02114	04-2697983	501(c)(3)	212,439	Neuroimaging Markers Predict Cognitive Decline in PD
(73) Max Planck Florida Institute 5353 Parkside Drive MC19-RE Jupiter,FL334582906	26-2117502	501(c)(3)	20,240	Design of HdAd Type 5 LRRK2 expression vectors
(74) Max Planck Florida Institute 5353 Parkside Drive MC19-RE Jupiter,FL334582906	26-2117502	501(c)(3)	36,947	Quality Control of HdAd Type 5 LRRK2 viral vectors
(75) Mayo Clinic 13400 E Shea Blvd Scottsdale,AZ85259	59-3337028	501(c)(3)	15,000	Adler compensation for role APDC
(76) McLean Hospital 115 Mill St Belmont,MA02478	04-2697981	501(c)(3)	250,000	Does peripheral immune challenge exacerbate LRRK2-induced neuronal pathology?
(77) Medical University of South Carolina 326 Calhoun Street Suite 308 Charleston,SC29425	57-6000722	501(c)(3)	459,095	Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease
(78) Metabolic Solutions Development Company 161 E Michigan Ave 4th Floor Kalamazoo,MI49007	90-0736237	Public Sector	210,939	Potential of Novel Insulin Sensitizers to Treat Dyskinesia
(79) Michigan State University 333 Bostwick Ave NE East Lansing,MI49503	38-6005984	501(c)(3)	75,000	Nigrostriatal alpha-synuclein overexpression in young and aged rats LRRK
(80) Michigan State University 333 Bostwick Ave NE East Lansing,MI49503	38-6005984	501(c)(3)	200,000	Alpha-Synuclein Aggregation Leads to Loss of Functional Forms of the Protein and Toxicity.
(81) Michigan State University 333 Bostwick Ave NE East Lansing,MI49546	38-6005984	501(c)(3)	270,582	Amitriptyline as a dopamine neuroprotective therapy.
(82) NINDS 6001 Executive Blvd Suite 2203 Bethesda,MD20892	52-0858115	501(c)(3)	100,000	iPSC Agreement
(83) National Institute on Aging 35 Convent Drive Building 35 Room Bethesda,MD20892	52-2038294	501(c)(3)	122,165	Non-kinase targets in LRRK2 biology
(84) Neuroscience Associates 10915 Lake Ridge Drive Knoxville,TN379344919	62-1540123	Public Sector	68,610	Pathological Characterization of Wildtype Rats as a controls for CJ LRRK2 Rats
(85) Neuroscience Associates 10915 Lake Ridge Drive Knoxville,TN379344919	62-1540123	Public Sector	172,633	Pathological characterization of aged KO rats
(86) Neuroscience Associates 10915 Lake Ridge Drive Knoxville,TN379344919	62-1540123	Public Sector	245,874	Pathological Characterization of aSyn mouse models
(87) New York Institute of Technology Northern Boulevard Riland Building Old Westbury,NY115688000	11-1788788	501(c)(3)	75,000	The Effects of Tyrosine on Orthostatic Hypotension in Parkinson's Disease
(88) Northwestern University 710 North Lake Shore Drive 1425 A Chicago,IL60611	36-2167817	501(c)(3)	9,688	PPMI 2012: rsMRI Ancillary Study
(89) Northwestern University 710 North Lake Shore Drive 1425 A Chicago,IL60611	36-2167817	501(c)(3)	16,406	PPMI 2012: Cognitive Categorization Ancillary Study
(90) Northwestern University 710 North Lake Shore Drive 1425 A Chicago,IL60611	36-2167817	501(c)(3)	28,534	PPMI 2012: Steering Committee Support for Tanya Simuni
(91) Northwestern University 710 North Lake Shore Drive 1425 A Chicago,IL60611	36-2167817	501(c)(3)	112,500	PPMI 2012: Consulting Support for rsMRI Sub- study (2012-2015)
(92) Northwestern University 710 North Lake Shore Drive 1425 A Chicago,IL60611	36-2167817	501(c)(3)	186,250	PPMI Clinical Trial Site: Year Two
(93) Octagon Research Solutions Inc 585 E Swedesford Road Suite 200 Wayne,PA19087	23-3022539	Public Sector	38,000	eCTD IND Submission for the AVE8112 MAD study
(94) Oregon Health & Science University 3181 SW Sam Jackson Park Rd OP-32 Portland,OR97239	93-1176109	501(c)(3)	15,938	PPMI 2012: Cognitive Categorization Ancillary Study
(95) Oregon Health & Science University 3181 SW Sam Jackson Park Road Portland,OR97239	93-1176109	501(c)(3)	30,000	Investigation of possible pathological changes in aged LRRK2 knockout rats
(96) Parexel 1560 Chevy Chase Drive Suite 140 Glendale,CA91206	04-3517643	Public Sector	211,800	Parexel Regulatory Services-Sanofi Trial
(97) Parexel 1560 Chevy Chase Drive Suite 140 Glendale,CA91206	04-3517643	Public Sector	1,116,184	Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AVE8112 in Patients with Parkinson's Disease
(98) Parkinson's Action Network 1025 Vermont Ave NW Suite 1120 Washington,DC20005	94-3172675	501(c)(3)	250,000	PAN Funding 2012
(99) Parkinson's Disease and Movement Disorder C 951 NW 13th Street Bldg 5-E Boca Raton,FL33486	22-3659456	501(c)(3)	14,063	PPMI 2012: Cognitive Categorization Ancillary Study
(100) Pfizer Global Research and Development Eastern Point Road Groton,CT06340	14-1396954	Public Sector	216,934	LRRK2 PET Tracer Development
(101) Promentis Pharmaceuticals 826 N Plankinton Ave Suite 4000 Milwaukee,WI80021	75-3234358	Public Sector	299,384	Targeting System-xc for the Treatment of Parkinson's Disease
(102) Proteos 4717 Campus Drive Kalamazoo,MI49008	26-0069252	Public Sector	31,003	Asyn Filament Antibody
(103) Proteos 4717 Campus Drive Kalamazoo,MI49008	26-0069252	Public Sector	69,311	Post-Translationally Modified Alpha-Synuclein: Generation of Alpha-Synuclein Protein
(104) PsychoGenics 765 Old Saw Mill River Road Suite Tarrytown,NY10591	13-4034631	Public Sector	206,000	Supplement to Phenotyping assessment of a DJ1 and Pink1 KO rats for PD
(105) Purdue University 550 Stadium Mall Dr West Lafayette,IN47907	35-6002041	501(c)(3)	250,000	Parkinson's and inflammatory bowel diseases: interaction in LRRK2 transgenic rats
(106) QR Pharma 1055 Westlakes Drive Suite 300 Berwyn,PA19312	26-2540421	Public Sector	468,640	Development of Posiphen to treat Parkinson's Disease
(107) Rush University 1735 West Harrison Street Suite 30 Chicago,IL60612	36-2174823	501(c)(3)	31,250	Rush University Tissue Resource
(108) Rush University 1725 W Harrison St Suite 755 Chicago,IL60612	36-2174823	501(c)(3)	111,875	BioFIND Clinical Trial Site: Rush University
(109) Rush University 1735 West Harrison Street Suite 30 Chicago,IL60612	36-2174823	501(c)(3)	491,803	The transfer of alpha-synuclein: Mechanistic and therapeutic studies
(110) Rush University 1725 W Harrison Suite 755 Chicago,IL60612	36-2174823	501(c)(3)	1,007,721	TOPIRAMATE AS AN ADJUNCT TO AMANTADINE IN THE TREATMENT OF DYSKINESIA IN PARKINSON'S Disease
(111) Sanford-Burnham Institute for Medical Research 10901 N Torrey Pines Rd La Jolla,CA92037	51-0197108	501(c)(3)	124,320	Protein S-Nitrosylation as a Potential Biomarker for Parkinson's Disease
(112) Sensonics Inc PO Box 112 Haddon Heights,NJ08035	23-2225611	Public Sector	25,710	PPMI 2012: 1st Batch Order of UPSITS for Prodromal PPMI (P-PPMI) - Dec 2012
(113) Sigma-Aldrich 2033 Westport Center Drive St Louis,MO63146	84-1656258	Public Sector	6,496	Sage LRRK2 KO Rat Pathology Study
(114) Sigma-Aldrich 1140 OBrien Drive suite A Menlo Park,CA94025	84-1656258	Public Sector	204,538	Sigma-Cell Lines
(115) Southern Research Institute 2000 Ninth Ave South Birmingham,AL35205	63-0288868	501(c)(3)	59,956	VILIP-1 as diagnostic and prognostic biomarker for Parkinson's Disease
(116) Stanford University 300 Pasteur Drive Room H3160 Stanford,CA94305	94-1156365	501(c)(3)	237,525	Small molecule ligand for TrkB/TrkC as a novel therapeutic for Parkinson's Disease
(117) Stanford University 1201 Welch Rd MSLS Building P304 Stanford,CA943055487	94-1156365	501(c)(3)	249,896	The Four Horsemen of G2019S
(118) State University of New York at Binghamton 4400 Vestal Parkway East Science 4 Binghamton,NY13902	14-1368361	501(c)(3)	74,944	Potential of concomitant targeting of 5-HT1A and 5-HT2A receptors against L-DOPA induced dyskinesia in the hemi-parkinsonian rat model
(119) SUNY Downstate Medical Center 450 Clarkson Ave Brooklyn,NY11203	14-1368361	501(c)(3)	311,521	Intrinsic Remodeling of the Fovea in Parkinson's Disease
(120) Taconic 5 Cedar Brook Drive Cranbury,NJ08512	33-0675808	Public Sector	55,162	Breeding and aging of aSyn mouse models at Taconic
(121) Taconic 5 Cedar Brook Drive Cranbury,NJ08512	33-0675808	Public Sector	55,399	Breeding and Aging of SD Wildtype Littermate Rats as controls for CJ Li LRRK2 Rats
(122) Taconic 5 Cedar Brook Drive Cranbury,NJ08512	33-0675808	Public Sector	80,363	Housing of CJ Li-generated BAC LRRK2 rats at Taconic
(123) Taconic 5 Cedar Brook Drive Cranbury,NJ08512	33-0675808	Public Sector	100,000	Taconic additional housing and breeding supplement
(124) Taconic 5 Cedar Brook Drive Cranbury,NJ08512	33-0675808	Public Sector	174,051	Housing of CJ Li-generated BAC alpha-synuclein rats at Taconic
(125) Texas A&M University Department of Pathobiology 218 VMA College Station,TX77843	74-2245072	501(c)(3)	150,000	The role of alpha-synuclein in the pathogenesis of Parkinson's disease in a rat model- SUPPLEMENT
(126) The Institute for Neurodegenerative Disorders 60 Temple St Suite 8B New Haven,CT06511	06-1582206	501(c)(3)	6,000	PPMI Data Entry for Q1 2012
(127) The Institute for Neurodegenerative Disorders 60 Temple St Suite 8B NEW HAVEN,CT06511	06-1582206	501(c)(3)	7,500	PPMI Data Entry for Q2 2012
(128) The Institute for Neurodegenerative Disorders 60 Temple St Suite 8B New Haven,CT06511	06-1582206	501(c)(3)	7,500	PPMI Data Entry for Q3 2012
(129) The Institute for Neurodegenerative Disorders 60 Temple St Suite 8B New Haven,CT06511	06-1582206	501(c)(3)	22,969	PPMI 2012: Cognitive Categorization Ancillary Study
(130) The Institute for Neurodegenerative Disorders 60 Temple St Suite 8B New Haven,CT06510	06-1582206	501(c)(3)	23,750	PPMI 2012: Leadership Core Support for AV133 Sub Study
(131) The Institute for Neurodegenerative Disorders 60 Temple St Suite 8B New Haven,CT06511	06-1582206	501(c)(3)	50,000	AV-133: PPMI Ancillary Study
(132) The Institute for Neurodegenerative Disorders 60 Temple St Suite 8B New Haven,CT06510	06-1582206	501(c)(3)	60,000	PPMI 2012: Leadership Core Support for P-PPMI
(133) The Institute for Neurodegenerative Disorders 60 Temple St Suite 8B New Haven,CT06510	06-1582206	501(c)(3)	114,000	PPMI 2012: Imaging Core Support for rsMRI Sub study
(134) The Institute for Neurodegenerative Disorders 60 Temple St Suite 8B New Haven,CT06510	06-1582206	501(c)(3)	166,667	PPMI 2012: 2013 Imaging Core Support for P-PPMI (LRRK2)
(135) The Institute for Neurodegenerative Disorders 60 Temple St Suite 8B New Haven,CT06510	06-1582206	501(c)(3)	176,250	PPMI 2012: Imaging Core Support for AV133 Sub study
(136) The Institute for Neurodegenerative Disorders 60 Temple St Suite 8B New Haven,CT06510	06-1582206	501(c)(3)	333,333	PPMI 2012: 2013 Imaging Core Support for P-PPMI
(137) The Institute for Neurodegenerative Disorders 60 Temple St Suite 8B New Haven,CT06511	06-1582206	501(c)(3)	350,000	PPMI 2012: Olfactory Core Support
(138) The Institute for Neurodegenerative Disorders 60 Temple St Suite 8B New Haven,CT06510	06-1582206	501(c)(3)	352,678	PPMI 2012: Leadership Core Year 3 Funding Support
(139) The Institute for Neurodegenerative Disorders 60 Temple St Suite 8B New Haven,CT06510	06-1582206	501(c)(3)	500,000	PPMI 2012: Site Support for Prodromal PPMI (P-PPMI) through Leadership Core - Dec 2012
(140) The Institute for Neurodegenerative Disorders 60 Temple St Suite 8B New Haven,CT06510	06-1582206	501(c)(3)	621,284	PPMI 2012: Imaging Core - Year 3 Funding Support
(141) The Jackson Laboratory 610 Main Street Bar Harbor,ME04609	01-0211513	501(c)(3)	7,000	GBA knockin mouse rederivation and housing
(142) The Jackson Laboratory 600 Main Street Bar Harbor,ME04609	01-0211513	501(c)(3)	96,591	Breeding and aging of aSyn mouse models at JAX
(143) The Parkinson's Institute 675 Almanor Avenue Sunnyvale,CA94085	94-3061594	501(c)(3)	10,781	PPMI 2012: Cognitive Categorization Ancillary Study
(144) The Parkinson's Institute 675 Almanor Avenue Sunnyvale,CA94085	94-3061594	501(c)(3)	36,632	PPMI 2012: 2012 Steering Committee Support for Carolline Tanner
(145) The Parkinson's Institute 675 Almanor Avenue Sunnyvale,CA94089	94-3061594	501(c)(3)	51,984	Assessing Heart Rate Variability (HRV) in the Parkinson's Associated Risk Study (PARS) Cohort - Part 2
(146) The Parkinson's Institute 675 Almanor Avenue Sunnyvale,CA94089	94-3061594	501(c)(3)	100,000	2012 Pritzker Prize - winner
(147) The Parkinson's Institute 675 Almanor Avenue Sunnyvale,CA94085	94-3061594	501(c)(3)	138,996	The effects of memantine on L-DOPA induced dyskinesias in MPTP-treated squirrel monkeys
(148) The Parkinson's Institute 675 Almanor Avenue Sunnyvale,CA94085	94-3061594	501(c)(3)	229,406	PPMI Clinical Trial Site: Year Two
(149) The Parkinson's Institute 675 Almanor Avenue Sunnyvale,CA94085	94-3061594	501(c)(3)	249,764	Establishing LRRK2 Signaling Pathways
(150) The Parkinson's Institute 675 Almanor Avenue Sunnyvale,CA94085	94-3061594	501(c)(3)	278,444	Combined therapy with amantadine and fenobam for L-DOPA induced dyskinesias in MPTP- treated squirrel monkeys
(151) The Parkinson's Institute 675 Almanor Avenue Sunnyvale,CA94085	94-3061594	501(c)(3)	411,020	Bay Area Solvent Study - Symptoms (BASS-S)
(152) The Parkinson's Institute 675 Almanor Avenue Sunnyvale,CA94085	94-3061594	501(c)(3)	475,375	Parkinson's Institute LRRK2 cohort: clinical phenotype, pre/non-motor and environmental risk assessment
(153) The Salk Institute for Biological Studies 10010 N Torrey Pines Road La Jolla,CA920371099	95-2160097	501(c)(3)	75,000	A Pair of Neurotrophic Factor Inducing Drug Candidates
(154) Thomas Jefferson University 1020 Locust Street 521 JAH Philadelphia,PA19107	23-2829095	501(c)(3)	74,967	Enzymatic Degradation of Brain Complex Gangliosides to Increase Endogenous GM1 Levels: Potential Neuroprotective/ Neurorestorative Therapy For Parkinson's Disease
(155) Thomas Jefferson University 900 Walnut Street-JHN Suite 462 Philadelphia,PA19107	23-2829095	501(c)(3)	114,618	Characterization of the hTH-GFP rat
(156) Thomas Jefferson University 900 Walnut Street-JHN Suite 462 Philadelphia,PA19107	23-2829095	501(c)(3)	139,380	Gremlin-1 a putative VTA-derived Neuroprotective Factor in Parkinson's disease
(157) Thomson Reuters 169 Saxony Road Suite 104 Encinitas,CA92024	23-1569117	Public Sector	19,000	Grant Outcomes Analysis
(158) University of Alabama at Birmingham 1719 6th Ave South CIRC 516 Birmingham,AL352940021	63-6005396	501(c)(3)	15,469	PPMI 2012: Cognitive Categorization Ancillary Study
(159) University of Alabama at Birmingham 1530 3rd Avenue South Birmingham,AL352941150	63-6005396	501(c)(3)	125,047	Targeting the JAK/STAT Pathway in the Treatment of Parkinson's Disease
(160) University of Alabama at Birmingham 1719 6th Ave S CIRC 516 Birmingham,AL35294	63-6005396	501(c)(3)	200,000	Role of LRRK2 in alpha-synuclein-induced neurodegeneration
(161) University of Arizona 1501 N Campbell Ave PO Box 2450 Tucson,AZ857245023	74-2652689	501(c)(3)	75,000	Opioid glycopeptides for the treatment of levodopa-induced dyskinesias
(162) University of California Berkeley 127 Morgan Hall Berkeley,CA94720	94-6002123	501(c)(3)	250,000	Monoacylglycerol Lipase as a Novel Target for Combatting Parkinson's Disease
(163) University of California Los Angeles 635 Charles E Young Drive South Los Angeles,CA900957334	95-6006143	501(c)(3)	14,583	PPMI 2012: Bioinformatics Core Support for Prodromal PPMI (P-PPMI) in 2013 - LRRK2 Contribution
(164) University of California Los Angeles 635 Charles E Young Drive South S Los Angeles,CA900957334	95-6006143	501(c)(3)	29,167	PPMI 2012: Support for Bioinformatics Core for Prodromal PPMI (P-PPMI) in 2013
(165) University of California Los Angeles 635 Charles E Young Drive South S Los Angeles,CA900957334	95-6006143	501(c)(3)	33,750	PPMI 2012: Bioinformatics Core Support for rsMRI Sub study
(166) University of California Los Angeles 635 Charles E Young Drive South S Los Angeles,CA900957334	95-6006143	501(c)(3)	49,375	PPMI2012: Bioinformatics Core Support for AV 133 Sub study
(167) University of California Los Angeles 635 Charles E Young Drive South S Los Angeles,CA900957334	95-6006143	501(c)(3)	53,750	PPMI 2012: Bioinformatics Core Support for Cognitive Categorization Ancillary Study
(168) University of California Los Angeles 635 Charles E Young Drive South S Los Angeles,CA900957334	95-6006143	501(c)(3)	315,928	PPMI 2012: Bioinformatics Core Year 3 Funding Support
(169) University of California San Diego 9500 Gilman Drive 0662 San Diego,CA920930662	95-2544535	501(c)(3)	7,031	PPMI 2012: Cognitive Categorization Ancillary Study
(170) University of California San Francisco 4150 Clement St 114M San Francisco,CA94121	94-6036493	501(c)(3)	97,961	PPMI 2012: Year 3 Funding Support for DTI Core
(171) University of California San Francisco 1650 Owens Street San Francisco,CA94158	94-6036493	501(c)(3)	200,000	Normal role of synuclein in mitochondrial bioenergetics at the synapse
(172) University of California San Francisco 1855 Folsom St Box 555 MCB Room San Francisco,CA94103	94-6036493	501(c)(3)	2,036,664	A Phase 1 Bridging Study of Adeno-Associated Virus Encoding Human Aromatic L-Amino Acid Decarboxylase (AAV2-hAADC) Administered by MRI-Guided Real-Time Convective Infusion in the Putamen of Subjects with Parkinson's Disease
(173) University of Chicago 5841 S Maryland Avenue MC 2030 Chicago,IL60637	36-2177139	501(c)(3)	48,202	A Small Molecule Approach to Correct Striatal Cholinergic Interneuron Dysfunction
(174) University of Chicago 924 East 57th Street Knapp Center Chicago,IL60637	36-2177139	501(c)(3)	75,000	Reversing pre-existing pathologies of DA neurons in a novel inducible human alpha- synuclein transgenic mouse model.
(175) University of Chicago 5841 S Maryland Avenue MC 2030 Chicago,IL60637	36-2177139	501(c)(3)	95,829	BioFIND- Oversite PI award
(176) University of Chicago 5841 S Maryland Ave MC2030 Room Chicago,IL60637	36-2177139	501(c)(3)	111,875	BioFIND Clinical Trial Site: University of Chicago
(177) University of Cincinnati 260 Stetson St Suite 2300 Cincinnati,OH45267	31-6000989	501(c)(3)	14,063	PPMI 2012: Cognitive Categorization Ancillary Study
(178) University of Cincinnati 3225 Eden Ave 136 HPB Cincinnati,OH45267	31-6000989	501(c)(3)	74,999	THE MIFUNCTIONAL CEMBRANOIDS FOR THERAPY OF PARKINSON'S DISEASE
(179) University of Cincinnati 260 Stetson St Suite 2300 Cincinnati,OH45267	31-6000989	501(c)(3)	326,969	PPMI Clinical Trial Site
(180) University of Colorado Denver 12850 E Montview Blvd Mail Stop Aurora,CO800452605	84-6000555	501(c)(3)	415,151	Optimizing Glyoxylate Metalloporphryins for Clinical Development in Parkinson's disease: Evaluation in the Rat 6OHDA Model
(181) University of Florida 100 S Newell Dr Room L1-100A Gainesville,FL32610	59-6002052	501(c)(3)	79,482	In Vivo Characterization of Helper-Dependent Adenoviral Vectors Expressing Human LRRK2
(182) University of Florida 100 S Newell Dr Room L1-100A Gainesville,FL32610	59-6002052	501(c)(3)	273,186	Development of appropriate control transgenes for long term viral vector mediated gene transfer and optical imaging in the Nigra
(183) University of Iowa 2450 University Capitol Center Iowa City,IA52242	42-6004813	501(c)(3)	9,167	PPMI 2012: 2013 Statistics Core Support for P-PPMI (LRRK2)
(184) University of Iowa 2450 University Capitol Center Iowa City,IA52242	42-6004813	501(c)(3)	18,333	PPMI 2012: 2013 Statistics Core Support for P-PPMI
(185) University of Iowa 2450 University Capitol Center Iowa City,IA52242	42-6004813	501(c)(3)	215,426	PPMI 2012: Statistics Core Year 3 Funding Report
(186) University of Michigan 1500 East Medical Center Drive Ann Arbor,MI481090028	38-6006309	501(c)(3)	1,000,000	The Role of A-beta in the Progression of Cognitive Impairment in PD: A Prospective Cohort Study
(187) University of Minnesota 516 Delaware St SE 12-146 P W B Minneapolis,MN55455	41-6007513	501(c)(3)	116,775	BioFIND Clinical Trial Site: University of Minnesota
(188) University of North Carolina at Chapel Hill 101 Manning Drive Chapel Hill,NC27599	56-6001393	501(c)(3)	6,579	HD-AD5 UNC SMALL BATCH/ DISTRIBUTION
(189) University of Pennsylvania 330 South 9th Street Philadelphia,PA19104	23-1352685	501(c)(3)	13,594	PPMI 2012: Cognitive Categorization Ancillary Study
(190) University of Pennsylvania 330 South 9th Street Philadelphia,PA19107	23-1352685	501(c)(3)	28,813	PPMI 2012: 2012 Steering Committee Support for Andrew Siderowf
(191) University of Pennsylvania 125 S 31st Street Philadelphia,PA19104	23-1352685	501(c)(3)	30,122	PPMI: Support for Ethics Component of Prodromal Study
(192) University of Pennsylvania 330 South 9th Street Philadelphia,PA19104	23-1352685	501(c)(3)	50,000	AV-133: PPMI Ancillary Study
(193) University of Pennsylvania 3600 Spruce St Maloney Bldg 3rd Philadelphia,PA19104	23-1352685	501(c)(3)	124,984	Evaluation of the Microtubule-Stabilizing Agent, Epothilone D, in Mouse Models of Parkinson's Disease
(194) University of Pennsylvania 330 South 9th Street Philadelphia,PA19104	23-1352685	501(c)(3)	147,500	PPMI Clinical Trial Site: Year Two
(195) University of Pennsylvania 3400 Spruce Street 7103 Founders Philadelphia,PA19104	23-1352685	501(c)(3)	300,134	PPMI 2012: Year 3 Funding Support for Bioanalytics Core
(196) University of Rochester 919 Westfall Road Building C Suit Rochester,MI14618	26-3800000	501(c)(3)	11,719	PPMI 2012: Cognitive Categorization Ancillary Study
(197) University of Rochester 265 Crittenden Blvd Rochester,NY14620	26-3800000	501(c)(3)	13,500	Datatop Samples Statistical Support from CHET, University of Rochester- Supplement
(198) University of Rochester 265 Crittenden Blvd Rochester,NY14620	26-3800000	501(c)(3)	15,938	Datatop Samples Statistical Support from CHET, University of Rochester
(199) University of Rochester 919 Westfall Road Building C Suit Rochester,NY14618	26-3800000	501(c)(3)	224,500	PPMI Clinical Trial Site: Year 2
(200) University of Rochester 265 Crittenden Blvd Rochester,NY14620	26-3800000	501(c)(3)	335,000	CTCC-PI for Discovery Cohort
(201) University of Rochester 1351 Mt Hope Avenue Suite 216 Rochester,NY14620	26-3800000	501(c)(3)	852,238	PPMI 2012: Year 3 Funding Support for the PPMI Clinical Core
(202) University of South Florida 4001 East Fletcher Avenue 6th Floo Tampa,FL33613	59-3102112	501(c)(3)	16,875	PPMI 2012: Cognitive Categorization Ancillary Study
(203) University of South Florida 4001 East Fletcher Avenue 6th Floo Tampa,FL33613	59-3102112	501(c)(3)	173,750	PPMI Clinical Trial Site: Year Two
(204) University of Texas Health Science Center San An 7703 Floyd Curl Drive San Antonio,TX78229	74-1586031	501(c)(3)	125,000	Novel cell-based strategy for GDNF delivery in Parkinson's disease
(205) University of Washington 1660 S Columbian Way VA-PSHCS 11 Seattle,WA98108	91-6001537	501(c)(3)	15,469	PPMI 2012: Cognitive Categorization Ancillary Study
(206) University of Washington 300 9th Ave RT Room 321 Seattle,WA98124	91-6001537	501(c)(3)	74,892	Phosphorylated alpha-synuclein species as biomarkers for diagnosis and progression in Parkinson's disease
(207) University of Washington 1660 S Columbian Way VA-PSHCS 11 Seattle,WA98108	91-6001537	501(c)(3)	170,000	PPMI Clinical Trial Site: Year Two
(208) UT Southwestern Medical Center at Dallas 5323 Harry Hines Blvd Mail Code 88 Dallas,TX753908813	75-6002868	501(c)(3)	43,915	Analysis of archived tissue from Parkin, DJ-1, PINK1 and LRRK2 KO rats
(209) UT Southwestern Medical Center at Dallas 5323 Harry Hines Blvd Mail Code 88 Dallas,TX753908813	75-6002868	501(c)(3)	275,000	Mechanisms of cellular regulation and post- translational modification of LRRK2
(210) Van Andel Research Institute 333 Bostwick Avenue NE Grand Rapids,MI49503	52-2000823	501(c)(3)	99,779	Circulating microRNAs: a new paradigm for Parkinson's disease biomarker discovery
(211) Vanderbilt University PHV Suite 313 1601 23rd Ave Sout Nashville,TN37212	62-0476822	501(c)(3)	98,894	Preferential loss of serotonin axon subtypes in depression in Parkinson's Disease
(212) Virginia College of Osteopathic Medicine 1861 Pratt Drive Corp Res Ctr - Blacksburg,VA24060	54-2052107	501(c)(3)	189,519	Cerium Oxide Nanoparticles in the Treatment of Parkinson's Disease - Toxicity & Biodistribution Studies
(213) Virginia Commonwealth University PO Box 980539 Richmond,VA55905	54-6001758	501(c)(3)	107,492	A Randomized Controlled Trial of Neurocognitive and Supportive Therapy Interventions for Individuals with Parkinson's Disease
(214) Washington State University Pullman Dept VCAPP Pullman,WA991646520	91-6001108	501(c)(3)	74,999	Development of Small Molecule Hepatocyte Growth Factor Mimetics for the Treatment of Parkinson's Disease
(215) Washington University in St Louis 510 S Kingshighway Blvd St Louis,MO63110	43-0653611	501(c)(3)	200,000	Alpha Synuclein Autoradiography Core
(216) Weill Medical College of Cornell University 428 East 72nd Street Suite 400 New York,NY10021	13-1623978	501(c)(3)	111,875	BioFIND Clinical Trial Site: Cornell University
(217) WIL Research Laboratories 1407 George Road Ashland,OH448058946	26-0564612	Public Sector	25,500	Collection and storage of rodent brain and peripheral tissues- Supplement
(218) WIL Research Laboratories 1407 George Road Ashland,OH448058946	26-0564612	Public Sector	63,000	Phenotypic Characterization of Wildtype Rats as a controls for CJ LRRK2 Rats
(219) WIL Research Laboratories 1407 George Road Ashland,OH448058946	26-0564612	Public Sector	142,500	SAGE LRRK2 KO RAT PATHOLOGY STUDY
(220) WIL Research Laboratories 1407 George Road Ashland,OH448058946	26-0564612	Public Sector	315,000	Behavioral Characterization of aSyn mouse models
(221) World Parkinson Coalition Inc 1359 Broadway Suite 1509 New York,NY10018	57-1206493	501(c)(3)	51,555	3rd World Parkinson Congress (WPC 2013)
(222) XenoPort 3410 Central Expressway Santa Clara,CA95051	94-3330837	Public Sector	347,075	Novel Fumarate Esters as Neuroprotective Agents in Parkinson's Disease

Enter total number of section 501(c)(3) and government organizations listed in the line 1 table ................ Bullet Image

167

Enter total number of other organizations listed in the line 1 table ........................ . Bullet Image

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 50055P

Schedule I (Form 990) 2012

Page 2

Part III

Grants and Other Assistance to Individuals in the United States. Complete if the organization answered "Yes" to Form 990, Part IV, line 22.
Part III can be duplicated if additional space is needed.

(a)Type of grant or assistance	(b)Number of recipients	(c)Amount of cash grant	(d)Amount of non-cash assistance	(e)Method of valuation (book, FMV, appraisal, other)	(f)Description of non-cash assistance

Part IV

Supplemental Information.

Complete this part to provide the information required in Part I, line 2, Part III, column (b), and any other additional information.

Identifier	Return Reference	Explanation
SCHEDULE I, PART I, LINE 2	PROCEDURES FOR MONITORING GRANT FUNDS IN THE UNITED STATES:	THE FOUNDATION AWARDS RESEARCH GRANTS BASED UPON THE GUIDANCE AND INPUT OF THE SCIENTIFIC ADVISORY BOARD AND OTHER HIGHLY REGARDED SCIENTISTS WHO SERVE ON GRANT REVIEW COMMITTEES SPECIALIZING IN PARKINSON'S RESEARCH. Goals and milestones are described within each grant award. Most Grant awards are allocated in multiple payments with key benchmarks set at the time of the grant award. MJFF's Research team closely monitors the progress of each grant awarded. There is frequent communication between grantees and MJFF staff regarding the progress of each grant. Progress is verified before additional payments are made.

Schedule I (Form 990) 2012

Additional Data

Software ID:
Software Version:

- TIN:

Schedule J
(Form 990)

Department of the Treasury
Internal Revenue Service

Compensation Information

For certain Officers, Directors, Trustees, Key Employees, and Highest
Compensated Employees
SchJMediumBullet

Complete if the organization answered "Yes" to Form 990,
Part IV, question 23.
SchJMediumBullet

Attach to Form 990. SchJMediumBullet

See separate instructions.

OMB No. 1545-0047

2012

Open to Public Inspection

Name of the organization

THE MICHAEL J FOX FOUNDATION
FOR PARKINSON'S RESEARCH

Employer identification number

13-4141945

Part I

Questions Regarding Compensation

Yes

Check the appropiate box(es) if the organization provided any of the following to or for a person listed in Form
990, Part VII, Section A, line 1a. Complete Part III to provide any relevant information regarding these items.

First-class or charter travel Housing allowance or residence for personal use

Travel for companions Payments for business use of personal residence

Tax idemnification and gross-up payments Health or social club dues or initiation fees

Discretionary spending account Personal services (e.g., maid, chauffeur, chef)

If any of the boxes in line 1a are checked, did the organization follow a written policy regarding payment or reimbursement or provision of all of the expenses described above? If "No," complete Part III to explain....

Did the organization require substantiation prior to reimbursing or allowing expenses incurred by all officers,
directors, trustees, and the CEO/Executive Director, regarding the items checked in line 1a? .......

Indicate which, if any, of the following the filing organization used to establish the compensation of the
organization's CEO/Executive Director. Check all that apply. Do not check any boxes for methods
used by a related organization to establish compensation of the CEO/Executive Director, but explain in Part III.

Compensation committee Written employment contract

Independent compensation consultant Compensation survey or study

Form 990 of other organizations Approval by the board or compensation committee

During the year, did any person listed in Form 990, Part VII, Section A, line 1a with respect to the filing organization or a related organization:

Receive a severance payment or change-of-control payment? ................

Participate in, or receive payment from, a supplemental nonqualified retirement plan? .........

Participate in, or receive payment from, an equity-based compensation arrangement? .........

If "Yes" to any of lines 4a-c, list the persons and provide the applicable amounts for each item in Part III.

Only 501(c)(3) and 501(c)(4) organizations only must complete lines 5-9.

For persons listed in Form 990, Part VII, Section A, line 1a, did the organization pay or accrue any
compensation contingent on the revenues of:

The organization? ...........................

Any related organization? .........................

If "Yes," to line 5a or 5b, describe in Part III.

For persons listed in Form 990, Part VII, Section A, line 1a, did the organization pay or accrue any
compensation contingent on the net earnings of:

The organization? ...........................

Any related organization? .........................

If "Yes," to line 6a or 6b, describe in Part III.

For persons listed in Form 990, Part VII, Section A, line 1a, did the organization provide any non-fixed
payments not described in lines 5 and 6? If "Yes," describe in Part III ............

Were any amounts reported in Form 990, Part VII, paid or accured pursuant to a contract that was
subject to the initial contract exception described in Regulations section 53.4958-4(a)(3)? If "Yes," describe
in Part III .............................

If "Yes" to line 8, did the organization also follow the rebuttable presumption procedure described in Regulations section 53.4958-6(c)? .........................

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 50053T

Schedule J (Form 990) 2012

Page 2

Part II

Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees. Use duplicate copies if additional space is needed.

For each individual whose compensation must be reported in Schedule J, report compensation from the organization on row (i) and from related organizations, described in the
instructions, on row (ii). Do not list any individuals that are not listed on Form 990, Part VII.
Note. The sum of columns (B)(i)-(iii) for each listed individual must equal the total amount of Form 990, Part VII, Section A, line 1a, applicable column (D) and (E) amounts for that individual.

(A) Name and Title		(B) Breakdown of W-2 and/or 1099-MISC compensation			(C) Retirement and other deferred compensation	(D) Nontaxable benefits	(E) Total of columns (B)(i)-(D)	(F) Compensation reported as deferred in prior Form 990
(A) Name and Title		(i) Base compensation	(ii) Bonus & incentive compensation	(iii) Other reportable compensation	(C) Retirement and other deferred compensation	(D) Nontaxable benefits	(E) Total of columns (B)(i)-(D)	(F) Compensation reported as deferred in prior Form 990
(1)Todd ShererCEO	(i) (ii)	280,616 0	165,000 0	0 0	7,500 0	18,590 0	471,706 0	0 0
(2)Joanne MartzChief Fin and Admin Officer	(i) (ii)	215,473 0	80,000 0	0 0	7,500 0	12,548 0	315,521 0	0 0
(3)Deborah W BrooksCo-Founder & Exec. Vice Chair	(i) (ii)	300,660 0	210,000 0	0 0	7,500 0	18,590 0	536,750 0	0 0
(4)Sohini ChowdhurySr. VP, Research Partnerships	(i) (ii)	180,396 0	30,000 0	0 0	6,312 0	6,140 0	222,848 0	0 0
(5)Sheila KellyVP, Development	(i) (ii)	165,363 0	19,500 0	0 0	5,546 0	6,139 0	196,548 0	0 0
(6)Holly TeichholtzVP, Marketing & Communications	(i) (ii)	130,286 0	15,000 0	0 0	4,359 0	12,548 0	162,193 0	0 0
(7)Brian K FiskeVP, Research Programs	(i) (ii)	169,200 0	17,500 0	0 0	5,387 0	12,548 0	204,635 0	0 0
(8)Mark A FrasierVP, Research Programs	(i) (ii)	160,352 0	17,500 0	0 0	5,335 0	0 0	183,187 0	0 0
(9)Alison UrkowitzVP, Research Operations	(i) (ii)	132,290 0	13,000 0	0 0	4,359 0	6,140 0	155,789 0	0 0
(10)Laxmi WordhamChief Digital Officer	(i) (ii)	200,440 0	30,000 0	0 0	6,913 0	18,590 0	255,943 0	0 0

Schedule J (Form 990) 2012

Page 3

Part III

Supplemental Information

Complete this part to provide the information, explanation, or descriptions required for Part I, lines 1a, 1b, 3, 4a, 4b, 4c, 5a, 5b, 6a, 6b, 7, and 8, and for Part II.
Also complete this part for any additional information.

Identifier	Return Reference	Explanation
DETERMINATION OF COMPENSATION FOR OFFICERS	SCHEDULE J, PART I, QUESTION 3	Compensation Determination: The Compensation Committee of the Board of Directors reviews and approves compensation of key employees annually.

Schedule J (Form 990) 2012

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE M
(Form 990)

Department of the Treasury

Internal Revenue Service

Noncash Contributions

Complete if the organizations answered "Yes" on Form 990, Part IV, lines 29 or 30.
Right pointing arrow large image

Attach to Form 990.

OMB No. 1545-0047

2012

Open to Public Inspection

Name of the organization

THE MICHAEL J FOX FOUNDATION
FOR PARKINSON'S RESEARCH

Employer identification number

13-4141945

Part I

Types of Property

	(a) Check if applicable	(b) Number of contributions or items contributed	(c) Noncash contribution amounts reported on Form 990, Part VIII, line 1g	(d) Method of determining noncash contribution amounts
1 Art—Works of art ....
2 Art—Historical treasures .
3 Art—Fractional interests ..
4 Books and publications ..
5 Clothing and household goods .......
6 Cars and other vehicles ..
7 Boats and planes ....
8 Intellectual property ...
9 Securities—Publicly traded .	X	57	33,493,293	FAIR VALUE
10 Securities—Closely held stock .
11 Securities—Partnership, LLC, or trust interests ....
12 Securities—Miscellaneous ..
13 Qualified conservation contribution—Historic structures .....
14 Qualified conservation contribution—Other ...
15 Real estate—Residential .
16 Real estate—Commercial ..
17 Real estate—Other ...
18 Collectibles .....
19 Food inventory ...
20 Drugs and medical supplies .
21 Taxidermy ......
22 Historical artifacts ....
23 Scientific specimens ..
24 Archeological artifacts ...
25 Other ( )
26 Other ( )
27 Other ( )
28 Other ( )

Number of Forms 8283 received by the organization during the tax year for contributions
for which the organization completed Form 8283, Part IV, Donee Acknowledgement ...

Yes

30a

During the year, did the organization receive by contribution any property reported in Part I, lines 1-28 that it

must hold for at least three years from the date of the initial contribution, and which is not required to be used

for exempt purposes for the entire holding period? ..................

30a

If "Yes," describe the arrangement in Part II.

Does the organization have a gift acceptance policy that requires the review of any non-standard contributions?

Yes

32a

Does the organization hire or use third parties or related organizations to solicit, process, or sell noncash

contributions? ..........................

32a

If "Yes," describe in Part II.

If the organization did not report an amount in column (c) for a type of property for which column (a) is checked,

describe in Part II.

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 51227J

Schedule M (Form 990) (2012)

Page 2

Part II

Supplemental Information. Complete this part to provide the information required by Part I, lines 30b,
32b, and 33, and whether the organization is reporting in Part I, column (b), the number of contributions, the number of items received, or a combination of both. Also complete this part for any additional information.

Identifier	Return Reference	Explanation

Schedule M (Form 990) (2012)

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE O
(Form 990 or 990-EZ)

Department of the Treasury
Internal Revenue Service

Supplemental Information to Form 990 or 990-EZ

Complete to provide information for responses to specific questions on
Form 990 or to provide any additional information.
MediumBullet

Attach to Form 990 or 990-EZ.

OMB No. 1545-0047

2012

Open to Public
Inspection

Name of the organization

THE MICHAEL J FOX FOUNDATION
FOR PARKINSON'S RESEARCH

Employer identification number

13-4141945

Identifier	Return Reference	Explanation
FORM 990, PAGE 1, LINE 1 AND PAGE 2, LINE 1		FINDING THE CURE FOR PARKINSONS TAKES AN ORGANIZATION WITH EXTRAORDINARY VISION. Actor Michael J. Fox established The Michael J. Fox Foundation for Parkinson's Research (the "Foundation"), incorporated in Delaware in 2000, after publicly disclosing in 1998 that he had been diagnosed with Parkinson's disease seven years earlier, at age 29. In 2009, The Michael J. Fox Foundation for Parkinson's Research in Canada ("MJFF Canada") was established as an officially registered tax-exempt charity in Canada. As this entity meets the criteria for consolidation, its financial statements are consolidated with those of the Foundation. As MJFF Canada's assets and liabilities and its operations were not significant at December 31, 2012 and 2011, they are not shown separately in the accompanying consolidated financial statements. The Foundation is exempt from federal income taxes under Section 501(c)(3) of the U.S. Internal Revenue Code, and from state and local taxes under comparable laws. MJFF Canada is exempt from similar taxes under Canadian law. Today, The Michael J. Fox Foundation is the world's largest private funder of Parkinson's research. It is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson's patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding more than $344 million in research as of December 31, 2012, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson's research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson's disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson's awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world. In addition to funding a broad portfolio of investigator-initiated and priority-driven research programs, the Foundation is working to transform the medical research enterprise and shape a system that fosters, rather than inhibits, the development of cures. MJFF partners with the Parkinson's research community, speeding financial and intellectual resources to the scientists who can help realize ideas with the greatest promise to impact patients' lives. The Foundation has ignited collaboration among academic and industry players by requiring researchers to share information in real time. To enable scientists to move toward breakthroughs faster, MJFF has stepped up to meet their need for research tools. To date, the Foundation has funded work on over 100 therapeutic targets, and is supporting 60 clinical trials. Since its founding, MJFF has proven not only that a new kind of stakeholder can accelerate drug development - but that it is what was missing all along. While much has changed in the past decade, one thing remains constant: the Foundation's commitment to Parkinson's patients. Everything MJFF does is with patients in mind, at all stages of PD, which informs investments in disease-modifying therapies, better symptomatic treatments and new approaches to the symptoms entirely unaddressed by today's generation of drugs.
Form 990, Page 6	Governance, Management and Disclosure	Line 2: BOARD MEMBER RELATIONSHIPS TWO BOARD MEMBERS ARE MARRIED TO ONE ANOTHER. TWO BOARD MEMBERS ARE IN-LAWS. Line 4: BY-LAW CHANGES DURING 2012, THE FOUNDATION REVISED ITS BY-LAWS. SIGNIFICANT CHANGES INCLUDE AN INCREASE IN THE MAXIMUM NUMBER OF DIRECTORS FROM 30 TO 50. Line 11A: Process for Review of Form 990: The Finance Committee of the Board of Directors, in association with external auditors, approves the annual IRS Form 990 which is then made available to the entire Board before it is filed. Line 12A: CONFLICT OF INTEREST POLICY Conflict of Interest Policy monitoring: Officers, directors and key employees complete a conflict of interest questionnaire annually. The information is reviewed by the Chief Financial and Administrative Officer, and conflicts are reviewed with the Board of Directors. Line 15: PROCESS FOR DETERMINING COMPENSATION Compensation Determination: The Compensation Committee of the Board of Directors reviews and approves compensation of key employees annually. Line 19: Governing documents are available upon request. - Conflict of interest policy is available upon request. - Financial statements are available at www.michaeljfox.org.

For Paperwork Reduction Act Notice, see the Instructions for Form 990 or 990-EZ.

Cat. No. 51056K

Schedule O (Form 990 or 990-EZ) 2012

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE R
(Form 990)

Department of the Treasury
Internal Revenue Service

Related Organizations and Unrelated Partnerships

Complete if the organization answered "Yes" to Form 990, Part IV, line 33, 34, 35, 36, or 37.
MediumBullet

Attach to Form 990. MediumBullet

See separate instructions.

OMB No. 1545-0047

2012

Open to Public Inspection

Name of the organization

THE MICHAEL J FOX FOUNDATION
FOR PARKINSON'S RESEARCH

Employer identification number

13-4141945

Part I

Identification of Disregarded Entities (Complete if the organization answered "Yes" to Form 990, Part IV, line 33.)

(a) Name, address, and EIN (if applicable) of disregarded entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Total income	(e) End-of-year assets	(f) Direct controlling entity

Part II

Identification of Related Tax-Exempt Organizations (Complete if the organization answered "Yes" to Form 990, Part IV, line 34 because it had one or more related tax-exempt organizations during the tax year.)

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Exempt Code section	(e) Public charity status (if section 501(c)(3))	(f) Direct controlling entity	(g) Section 512(b)(13) controlled entity?
(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Exempt Code section	(e) Public charity status (if section 501(c)(3))	(f) Direct controlling entity	Yes	No
(1) MJFF CANADA 365 Bay Street Suite 899 Toronto,Ontario CA	RESEARCH	CA			MJFF (US)		No

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 50135Y

Schedule R (Form 990) 2012

Page 2

Part III

Identification of Related Organizations Taxable as a Partnership (Complete if the organization answered "Yes" to Form 990, Part IV, line 34 because it had one or more related organizations treated as a partnership during the tax year.)

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(f) Share of total income	(g) Share of end-of-year assets	(h) Disproprtionate allocations?		(i) Code VUBI amount in box 20 of Schedule K-1 (Form 1065)	(j) General or managing partner?
(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(f) Share of total income	(g) Share of end-of-year assets	Yes	No	(i) Code VUBI amount in box 20 of Schedule K-1 (Form 1065)	Yes	No

Part IV

Identification of Related Organizations Taxable as a Corporation or Trust (Complete if the organization answered "Yes" to Form 990, Part IV, line 34 because it had one or more related organizations treated as a corporation or trust during the tax year.)

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(e) Type of entity (C corp, S corp, or trust)	(f) Share of total income	(g) Share of end-of-year assets	(i) Section 512(b)(13) controlled entity?
(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(e) Type of entity (C corp, S corp, or trust)	(f) Share of total income	(g) Share of end-of-year assets	Yes	No

Schedule R (Form 990) 2012

Page 3

Part V

Transactions With Related Organizations (Complete if the organization answered "Yes" to Form 990, Part IV, line 34, 35b, or 36.)

Note. Complete line 1 if any entity is listed in Parts II, III, or IV of this schedule.

Yes

1 During the tax year, did the orgranization engage in any of the following transactions with one or more related organizations listed in Parts II-IV?

a Receipt of (i) interest (ii) annuities (iii) royalties or (iv) rent from a controlled entity . . . . . . . . . . . . . . . . . . . . . . .

b Gift, grant, or capital contribution to related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

c Gift, grant, or capital contribution from related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Yes

d Loans or loan guarantees to or for related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

e Loans or loan guarantees by related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

f Dividends from related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

g Sale of assets to related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

h Purchase of assets from related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

i Exchange of assets with related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

j Lease of facilities, equipment, or other assets to related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . .

k Lease of facilities, equipment, or other assets from related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . .

l Performance of services or membership or fundraising solicitations for related organization(s) . . . . . . . . . . . . . . . . . . . .

m Performance of services or membership or fundraising solicitations by related organization(s) . . . . . . . . . . . . . . . . . . . .

n Sharing of facilities, equipment, mailing lists, or other assets with related organization(s) . . . . . . . . . . . . . . . . . . . . .

o Sharing of paid employees with related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

p Reimbursement paid to related organization(s) for expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

q Reimbursement paid by related organization(s) for expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

r Other transfer of cash or property to related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

s Other transfer of cash or property from related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

If the answer to any of the above is "Yes," see the instructions for information on who must complete this line, including covered relationships and transaction thresholds.

(a) Name of other organization	(b) Transaction type (a-s)	(c) Amount involved	(d) Method of determining amount involved
(1) THE MICHAEL J FOX FOUNDATION (CANADA)	C	293,559	FMV

Schedule R (Form 990) 2012

Page 4

Part VI

Unrelated Organizations Taxable as a Partnership (Complete if the organization answered "Yes" to Form 990, Part IV, line 37.)

Provide the following information for each entity taxed as a partnership through which the organization conducted more than five percent of its activities (measured by total assets or gross revenue) that was not a related organization. See instructions regarding exclusion for certain investment partnerships.

(a) Name, address, and EIN of entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	(e) Are all partners section 501(c)(3) organizations?		(f) Share of total income	(g) Share of end-of-year assets	(h) Disproprtionate allocations?		(i) Code VUBI amount in box 20 of Schedule K-1 (Form 1065)	(j) General or managing partner?
(a) Name, address, and EIN of entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	Yes	No	(f) Share of total income	(g) Share of end-of-year assets	Yes	No	(i) Code VUBI amount in box 20 of Schedule K-1 (Form 1065)	Yes	No

Schedule R (Form 990) 2012

Page 5

Part VII

Supplemental Information

Complete this part to provide additional information for responses to questions on Schedule R (see instructions).

Identifier	Return Reference	Explanation

Additional Data

Software ID:
Software Version:

1	Briefly describe the organization’s mission or most significant activities: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH IS DEDICATED TO ENSURING THE DEVELOPMENT OF BETTER TREATMENTS, AND ULTIMATELY A CURE, FOR PARKINSON'S DISEASE THROUGH AN AGRESSIVELY FUNDED RESEARCH AGENDA.
2	Check this box
3	Number of voting members of the governing body (Part VI, line 1a) ........	3	29
4	Number of independent voting members of the governing body (Part VI, line 1b) .....	4	28
5	Total number of individuals employed in calendar year 2011 (Part V, line 2a) ......	5	84
6	Total number of volunteers (estimate if necessary) .............	6	17
7a	Total unrelated business revenue from Part VIII, column (C), line 12 ........	7a	18,055
b	Net unrelated business taxable income from Form 990-T, line 34 .........	7b	210

		Prior Year	Current Year
8	Contributions and grants (Part VIII, line 1h) .........	64,970,818	87,327,249
9	Program service revenue (Part VIII, line 2g) .........	0	0
10	Investment income (Part VIII, column (A), lines 3, 4, and 7d ) ....	174,041	25,786
11	Other revenue (Part VIII, column (A), lines 5, 6d, 8c, 9c, 10c, and 11e)	38,514	183,056
12	Total revenue—add lines 8 through 11 (must equal Part VIII, column (A), line 12)...................	65,183,373	87,536,091
13	Grants and similar amounts paid (Part IX, column (A), lines 1–3 )...	53,857,613	55,079,865
14	Benefits paid to or for members (Part IX, column (A), line 4).....	0	0
15	Salaries, other compensation, employee benefits (Part IX, column (A), lines 5–10)	6,906,870	8,458,578
16a	Professional fundraising fees (Part IX, column (A), line 11e).....	60,000	0
b	Total fundraising expenses (Part IX, column (D), line 25) 5,746,832
17	Other expenses (Part IX, column (A), lines 11a–11d, 11f–24e)....	4,814,498	6,708,348
18	Total expenses. Add lines 13–17 (must equal Part IX, column (A), line 25)	65,638,981	70,246,791
19	Revenue less expenses. Subtract line 18 from line 12.......	-455,608	17,289,300
		Beginning of Current Year	End of Year
20	Total assets (Part X, line 16).............	95,542,240	105,378,503
21	Total liabilities (Part X, line 26).............	74,420,395	66,960,964
22	Net assets or fund balances. Subtract line 21 from line 20.....	21,121,845	38,417,539

Sign Here

	Signature of officer	Date

	Type or print name and title


4a	(Code: ) (Expenses $ 62,657,563 including grants of $ 55,079,865 ) (Revenue $ )
	TO FUND RESEARCH FOCUSED ON DEVELOPING A CURE FOR PARKINSON'S DISEASE.

4b	(Code: ) (Expenses $ including grants of $ ) (Revenue $ )












4c	(Code: ) (Expenses $ including grants of $ ) (Revenue $ )












4d	Other program services (Describe in Schedule O.)
	(Expenses $ including grants of $ ) (Revenue $ )
4e	Total program service expenses62,657,563

1b	Sub-Total................
c	Total from continuation sheets to Part VII, Section A....
d	Total (add lines 1b and 1c)............	2,532,576	0	172,544

(A) Name and business address	(B) Description of services	(C) Compensation
RUDER FINN INC, 301 E 57TH STREETNEW YORKNY10022	CONSULTING	198,726




2 Total number of independent contractors (including but not limited to those listed above) who received more than $100,000 of compensation from the organization 1

				(A) Total revenue	(B) Related or exempt function revenue	(C) Unrelated business revenue	(D) Revenue excluded from tax under sections 512, 513, or 514
1a	Federated campaigns..1a
b	Membership dues....1b
c	Fundraising events....1c		4,823,361
d	Related organizations...1d
e	Government grants (contributions)1e

f	All other contributions, gifts, grants, and similar amounts not included above1f		82,503,888

g	Noncash contributions included in lines 1a-1f:$		33,493,293
h	Total. Add lines 1a-1f.......			87,327,249
			Business Code
2a
b
c
d
e
f	All other program service revenue .
g	Total. Add lines 2a–2f........			0
3	Investment income (including dividends, interest, and other similar amounts).......			24,221			24,221
4	Income from investment of tax-exempt bond proceeds..			0
5	Royalties...........			0
		(i) Real	(ii) Personal
6a	Gross rents	161,299
b	Less: rental expenses
c	Rental income or (loss)	161,299	0
d	Net rental income or (loss).......			161,299			161,299
		(i) Securities	(ii) Other
7a	Gross amount from sales of assets other than inventory	33,562,803
b	Less: cost or other basis and sales expenses	33,561,238
c	Gain or (loss)	1,565
d	Net gain or (loss)..........			1,565			1,565
8a	Gross income from fundraising events (not including $ 4,529,802 of contributions reported on line 1c). See Part IV, line 18 ..
	a		913,395
b	Less: direct expenses ...b		913,395
c	Net income or (loss) from fundraising events..			0
9a	Gross income from gaming activities. See Part IV, line 19 ...
	a
b	Less: direct expenses ...b
c	Net income or (loss) from gaming activities...			0
10a	Gross sales of inventory, less returns and allowances .
	a		44,887
b	Less: cost of goods sold ..b		26,382
c	Net income or (loss) from sales of inventory..			18,055		18,055
Miscellaneous Revenue			Business Code
11a	MISCELLANEOUS REVENUE		900099	3,702			3,702
b
c
d	All other revenue ....
e	Total. Add lines 11a–11d ......			3,702
12	Total revenue. See Instructions......			87,536,091		18,055	190,787


				(A) Beginning of year		(B) End of year
1	Cashnon-interest-bearing .............			104	1	326
2	Savings and temporary cash investments .........			80,371,171	2	85,393,127
3	Pledges and grants receivable, net ...........			12,027,926	3	15,199,335
4	Accounts receivable, net .............			0	4	0
5	Loans and other receivables from current and former officers, directors, trustees, key employees, and highest compensated employees. Complete Part II of Schedule L ..................
				0	5	0
6	Loans and other receivables from other disqualified persons (as defined under section 4958(f)(1)), persons described in section 4958(c)(3)(B), and contributing employers and sponsoring organizations of section 501(c)(9) voluntary employees' beneficiary organizations (see instructions) Complete Part II of Schedule L
				0	6	0
7	Notes and loans receivable, net .............			0	7	0
8	Inventories for sale or use ..............			17,847	8	19,190
9	Prepaid expenses and deferred charges ..........			303,256	9	312,174
10a	Land, buildings, and equipment: cost or other basis. Complete Part VI of Schedule D	10a	3,832,472
b	Less: accumulated depreciation .....	10b	1,688,083	653,423	10c	2,144,389
11	Investments—publicly traded securities ..........			1,339,815	11	1,478,589
12	Investments—other securities. See Part IV, line 11 .....			0	12	0
13	Investments—program-related. See Part IV, line 11 .....			0	13	0
14	Intangible assets ...............			0	14	0
15	Other assets. See Part IV, line 11 ...........			828,698	15	831,373
16	Total assets. Add lines 1 through 15 (must equal line 34)......			95,542,240	16	105,378,503
17	Accounts payable and accrued expenses .........			1,590,225	17	2,186,550
18	Grants payable .................			56,245,521	18	62,405,623
19	Deferred revenue ................			14,898,701	19	0
20	Tax-exempt bond liabilities .............			0	20	0
21	Escrow or custodial account liability. Complete Part IV of Schedule D..			0	21	0
22	Loans and other payables to current and former officers, directors, trustees, key employees, highest compensated employees, and disqualified
	persons. Complete Part II of Schedule L..........			0	22	0
23	Secured mortgages and notes payable to unrelated third parties ..			0	23	0
24	Unsecured notes and loans payable to unrelated third parties ....			1,000,196	24	1,150,196
25	Other liabilities (including federal income tax, payables to related third parties, and other liabilities not included on lines 17-24). Complete Part X of Schedule D....................			685,752	25	1,218,595
26	Total liabilities. Add lines 17 through 25.........			74,420,395	26	66,960,964
	Organizations that follow SFAS 117 (ASC 958), check here and complete lines 27 through 29, and lines 33 and 34.
27	Unrestricted net assets ..............			5,774,290	27	18,533,026
28	Temporarily restricted net assets ...........			15,347,555	28	19,884,513
29	Permanently restricted net assets ...........			0	29	0
	Organizations that do not follow SFAS 117 (ASC 958), check here and complete lines 30 through 34.
30	Capital stock or trust principal, or current funds ........				30
31	Paid-in or capital surplus, or land, building or equipment fund .....				31
32	Retained earnings, endowment, accumulated income, or other funds				32
33	Total net assets or fund balances ...........			21,121,845	33	38,417,539
34	Total liabilities and net assets/fund balances ........			95,542,240	34	105,378,503

1	Was the organization a U.S. transferor of property to a foreign corporation during the tax year? If “Yes,”the organization may be required to file Form 926, Return by a U.S. Transferor of Property to a Foreign Corporation (see Instructions for Form 926)......................................	Yes	No
2	Did the organization have an interest in a foreign trust during the tax year? If “Yes,” the organizationmay be required to file Form 3520, Annual Return to Report Transactions with Foreign Trusts and Receipt of Certain Foreign Gifts, and/or Form 3520-A, Annual Information Return of Foreign Trust With a U.S. Owner (see Instructions for Forms 3520 and 3520-A).......................................	Yes	No
3	Did the organization have an ownership interest in a foreign corporation during the tax year? If "Yes," the organization may be required to file Form 5471, Information Return of U.S. Persons with Respect to Certain Foreign Corporations. (see Instructions for Form 5471)..............................	Yes	No
4	Was the organization a direct or indirect shareholder of a passive foreign investment company or a qualified electing fund during the tax year? If "Yes," the organization may be required to file Form 8621, Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund. (see Instructions for Form 8621)	Yes	No
5	Did the organization have an ownership interest in a foreign partnership during the tax year? If "Yes," the organization may be required to file Form 8865, Return of U.S. Persons with Respect to Certain Foreign Partnerships. (see Instructions for Form 8865)....................................	Yes	No
6	Did the organization have any operations in or related to any boycotting countries during the tax year? If "Yes," the organization may be required to file Form 5713, International Boycott Report (see Instructions for Form 5713)................................................	Yes	No